{
  "name" : "twin.sci-hub.se_6256_b64b4e875c68bac3cc1dd5e7506cc455_gong2017.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : null,
    "authors" : [ "Linji Gong", "Liang Yan", "Ruyi Zhou", "Jiani Xie", "Wei Wu", "Zhanjun Gu" ],
    "emails" : [ "zjgu@ihep.ac.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.\nAccepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.\nYou can find more information about Accepted Manuscripts in the author guidelines.\nPlease note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the ethical guidelines, outlined in our author and reviewer resource centre, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.\nAccepted Manuscript\nrsc.li/materials-b\nJournal of Materials Chemistry B Materials for biology and medicine www.rsc.org/MaterialsB\nISSN 2050-750X PAPER Guoping Chen et al. Regulating the stemness of mesenchymal stem cells by tuning micropattern features\nVolume 4 Number 1 7 January 2016 Pages 1–178\nJournal of Materials Chemistry B Materials for biology and medicine\nView Article Online View Journal\nThis article can be cited before page numbers have been issued, to do this please use: Z. Gu, L. Gong, L. YAN, R. Zhou, J. Xie and W. Wu, J. Mater. Chem. B, 2017, DOI: 10.1039/C7TB00195A.\nTwo-dimensional Transition Metal Dichalcogenides Nanomaterials for Combination\nTherapy of Cancer\nLinji Gong,a Liang Yan,a Ruyi Zhou,a Jiani Xie,a Wei Wu,b and Zhanjun Gu*a\na CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, 100049, China. b Southwest Hospital/Southwest Eye Hospital, Third Military Medical University, Chong Qing, 400038, China.\n*E-mail: zjgu@ihep.ac.cn\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nAbstract As demonstrated by the preclinical and clinical studies, photothermal therapy (PTT) alone is often difficult to eradicate tumors and kill the deep-located tumors because of the intrinsic drawbacks of optical therapy. To increase the therapeutic effect of PTT and reduce its significant side-effects, it is desired to spawn a new direction to combine PTT with other therapeutic techniques. Recently, two-dimensional (2D) transition metal dichalcogenides (TMDCs), as the typical ultrathin 2D layer nanomaterials, have gained tremendous interest in many different fields including biomedicine due to their novel physicochemical properties. Benefitting from their intrinsic near-infrared absorbance property and extremely large specific surface area, many efforts are being devoted to fabricating 2D TMDC-based multifunctional nanoplatform for combination PTT with other therapeutics in order to realize 2D TMDC-assisted combination therapy and thus achieve excellent anti-tumor therapeutic efficacy. In addition, various inorganic nanoparticles and fluorescent probes can be attached on the surface of 2D TMDCs to obtain nanocomposites with versatile optical and/or magnetic properties that are useful for multi-modal imaging and imaging-guided cancer therapy. In this review, we mainly summarize the latest advance in the utilization of 2D TMDCs for PTT combinational cancer therapy, including PTT/photodynamic therapy, PTT/chemotherapy, PTT/radiotherapy, PTT/gene therapy, and imaging-guided cancer combination therapy, as well as the evaluation of their behaviors and toxicology both in vitro and in vivo. Furthermore, we address the principle for design of 2D TMDC-assisted photothermal combination theranostics and the future prospects and challenges of using 2D TMDC-based nanomaterials for theranostic applications.\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3."
    }, {
      "heading" : "1. Introduction",
      "text" : "Despite the dramatic advances in prevention and treatment of cancer over the past decades, this disease is still one of the major causes that continues to threaten the health of millions of people worldwide. Therefore, it is of great significance to develop effective and safe cancer treatments to improve the quality of life, increase survival rate and most importantly, and extend human lives. With the rapid development of nanoscience, nanomaterial-assisted combination therapies have arguably become the most active area in medicine research, which represents the arrival of a new era of “cancer nanomedicine”.1-11 Among these treatment strategies, photothermal combination therapy, which refers to the simultaneous or continuous administration of nanomaterial-based photothermal therapy (PTT) with other therapeutic techniques, such as chemotherapy, shows a significant promise comparing to mono PTT because of its advantages in improving therapeutic efficacy, reducing side-effects and overcoming multi-drug resistance (MDR) (Fig. 1).12-15 Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.16-26 For example, Zhang et al. utilized PEGylated graphene oxide as a nanocarrier to load anticancer drug and where they demonstrated that the mice treated with the obtained nanocomplex showed more excellent therapeutic effect compared to those treated by drug or the nanocomposite with laser irradiation alone.27 More recently, driven by the success of graphene for biomedicine, the rapid progress of research has stimulated a lot of interest in other layered 2D nanomaterials.28-30 Previous studies on several representative 2D nanomaterials, such as black phosphorus (BP) nanosheets,31 boron nitride (BN),32-34 and graphitic carbon nitride (g-C3N4), 35-37 have successfully proved that 2D nanomaterials possess not only high photothermal conversion efficiency but also large surface area which are highly favorable to deliver biomolecules and drugs into cells for cancer treatment. Therefore, it should be expected that these graphene-like 2D nanomaterials are appealing candidates for photothermal combination therapy.\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nIn the rich family of 2D nanomaterials, 2D transition metal dichalcogenides (TMDCs) have becoming the focus of fundamental research and technological applications.38-42 Analogous to graphene, as shown in Fig. 2, 2D TMDCs consists a hexagonal layer of transition metal atoms (M) sandwiched between two layers of chalcogen atoms (X) with a MX2 stoichiometry, where M ranges from Group IVB to Group VIII (such as Ti, V, Nb, Mo, Hf, Ta, and W), and X stands for the chalcogen (S, Se, and Te).43-45 Together with topological insulators (such as Bi2Se3), more than 40 types of 2D TMDCs can occur depending on the combination of M and X as well as their diverse arrangements.43 This special structure and various combinations of atoms endow 2D TMDCs with a substantial range of properties (Fig. 2), such as unique electronic and optical properties,39, 44, 45 tunable energy band, large surface areas and low cytotoxicity,46-48 all of which make them suitable for applications in a large variety of fields including electronics, optics, nanocomposites, energy research and catalysis.49-57\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nFig. 2 The synthesis and selected characteristics of listed 2D TMDCs. (a) About 40 different layered TMDC compounds exist. The transition metals and the three chalcogen elements that predominantly crystallize in those layered structure are highlighted in the periodic table. Partial highlights for Co, Rh, Ir and Ni indicate that only some of the dichalcogenides form layered structures. For example, NiS2 is found to have apyrite structure but NiTe2 is a layered compound. (Reproduced with permission from ref. 44. Copyright 2013, Macmillan Publishers Limited). (b) Schematic representation of the synthetic methods to obtain multifunctional 2D materials. (Reproduced with permission from ref. 28. Copyright 2016, Jo\nur\nna lo\nfM\nat\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nWiley-VCH). The insets is the photographs of represented MoS2 and WS2 nanosheet dispersions. (Reprinted with permission from ref. 58. Copyright 2011, Wiley-VCH). (c) Three-dimensional representation of the structure of MoS2 with single layers being 6.5 Å thick. (Reprinted with permission from ref. 59. Copyright 2011, Macmillan Publishers Limited). Comparison of Raman spectra of (d) 1T-MoS2 and 2H-MoS2, (e) 1T-MoSe2 and 2H-MoSe2. (Reproduced with permission from ref. 60. Copyright 2014, AIP Publishing). (f) PL spectra of MoS2 under excitation wavelengths of 320-500 nm. (Reproduced with permission from ref. 61. Copyright 2014, American Chemical Society). (g) Energy level diagram of selected 2D TMDCs. (Reproduced with permission from ref. 40. Copyright 2015, Wiley-VCH).\nIn recent years, 2D TMDCs have also gained rapid momentum in the area of biomedicine.40, 41, 62 2D TMDCs with large surface area can interact with various biomolecules and anticancer drugs for applications in biosensors, drug delivery, gene transfection and tissue engineering.63-65 By utilizing their intrinsic high NIR absorbance as well as low toxicity, 2D TMDCs have also been used as photothermal agents for PTT of cancer with encouraging therapeutic outcomes.66-68 Therefore, thanks to their excellent photothermal effects, large surface area, and versatile surface chemistries, 2D TMDCs have great potential as a platform to integrate PTT with other therapeutic moieties, which endows them with highly enriched functionalities for cancer treatment (Fig. 1). Although some articles have given a systematic and detailed review on the applications of 2D TMDCs in the fields of biosensors, bioimaging and tissues engineering.40, 63, 69-71 The review focused on the summary of 2D TMDC-assisted combinational therapies is still rare. Therefore, to clearly diversify our contribution from other recent reviews on 2D TMDCs, we give a brief overview of recent works that emphasize the use of the NIR photothermal-respective 2D TMDCs for combination cancer therapy, and discuss their behaviors and toxicology both in vitro and in vivo, so as to open up new possibilities to develop 2D TMDC-assisted photothermal combination cancer therapy. We also address the principle for design of 2D TMDC-assisted photothermal combination theranostics and the future prospects and challenges in this newly and rapidly growing field. It is believed that such a review article could assist non-experts in understanding the latest progress, current limitations, as well as future directions of using 2D TMDCs for combination therapy of cancer.\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3."
    }, {
      "heading" : "2. Principle for design of 2D TMDC-assisted photothermal combination therapeutics",
      "text" : "As a promising supplement to conventional approaches in cancer treatment, PTT has increasingly attracted much attention because of its various advantages such as low cost, highly localized and specific tumor treatment, and few complications.72, 73 However, many preclinical and clinical studies have shown that PTT alone is often difficult to completely eradicate tumors due to the inhomogeneous heat distribution within tumor tissues and the failure of killing the deep-located tumors because of the inevitable depth-dependent decline of laser intensity, which are the intrinsic drawbacks of optical therapy.74 In addition, hyperthermia not only eradicate the cancer cells but also cause damage to healthy tissue, leading to potential side-effect. In a word, the development of mono-PTT has reached its bottleneck period, and it is desired to spawn a new direction to combine PTT with other therapeutic techniques. In fact, as demonstrated by many experimental studies and clinical trials, hyperthermia (41-45 ᵒC) is a powerful enhancer for radiotherapy (RT), chemotherapy, photodynamic therapy (PDT) and gene therapy (GT).75, 76 In the meantime, except PDT, other therapeutic modalities can largely overcome the above-mentioned drawbacks of PTT due to their superiority of unlimited penetration depth. Therefore, photothermal combination therapy can promote synergism among the different modalities against cancer cells, suppress their side-effects through multiple mechanisms such as sensitization and motivating anti-tumor immune function, and finally enhance the anti-cancer efficacy as well as avoid high-dose-induced toxicity toward normal tissue.75 Thus, photothermal combination therapy is of hope for the fabrication of the next generation of anticancer tools. In analogy to graphene, 2D TMDCs have also been used as photothermal agents for cancer treatment due to the NIR absorption ability. When irradiated with NIR light, they are capable of absorbing light energy and then generating sufficient heat to kill cancer cells. To combine PTT with other therapeutic modalities so as to enhance anticancer efficacy and optimize therapy, the commonly applied principles of design of 2D TMDC-assisted photothermal combination therapy are as follows. 1) Near-infrared absorption. It is generally believed that the NIR spectral range (700-1100 nm) is referred to as the optical window of bio-tissue, where the light scatting and absorbance of bio-tissue are minimum. Thus, NIR-responsive photothermal agents have attracted great interest in PTT since it offers greater penetration depth in bio-tissue. Most TMDCs have a\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nbroad absorption in the NIR region (700-1100 nm) due to their narrow band gap that expand the light absorption to NIR region. From this point of view, 2D TMDCs are ideal photothermal agents to convert NIR light into heat to kill cancer cells.77 2) High photothermal conversion efficiency. High power density NIR laser can cause burn wounds and shrinking of the tissue.78, 79 To achieve high PTT efficiency with a low power density of NIR light, it is required that photothermal agents possess high photothermal conversion efficiency in the NIR region. As expected, most 2D TMDCs exhibit a strong absorption in NIR region and display high photothermal conversion efficiency which is comparable to that of other nanoscale photothermal agents such as gold nanoparticles.66 3) High photostability. Photostability is an important prerequisite for photothermal agents as they may suffer from photobleaching or decomposition during the light irradiation. Therefore, photothermal agents with high photostability could avoid these drawbacks even under NIR irradiation while maintaining their intrinsic structures and properties. For 2D TMDCs, the excellent photostability as well as high photothermal conversion efficiency in the NIR region makes them suitable as therapeutic agents to kill cancer cells based on themselves without any additional components.80, 81 4) Large surface area. The 2D structure endows TMDCs with extremely high surface area. addition to the versatile surface chemistry, 2D TMDCs have great potential as a nanoplatform to integrate them with other functional moieties, endowing the obtained nanocomposites with highly enriched functionalities which are useful in extending their utilization to photothermal combination therapies. In practice, by utilizing the large surface area of 2D TMDCs, various kinds of therapeutic agents such as chemotherapy drugs, photosensitizers and genes, can be loaded on them through physical adsorption or chemical grafting for cancer treatments. It is worth noting that the 2D TMDCs can act as not only drug carriers but also a NIR-triggered platform for remote control of drug-payload release by photothermal effects. The increasing local temperature induced by photothermal carriers upon NIR irradiation can dissociate the interactions between drug molecules and carriers and thus more drug molecule are detached from the nanocarriers. This feature helps to realize the on-demand drug release at the desired site and time with controllable therapeutic outcome owing to the high spatial-temporal resolution of NIR light stimuli.82 On the other hand, a few 2D TMDCs that contain high Z elements such as WS2 and Bi2Se3 have strong X-ray attenuation ability, which makes them possible to be used as efficient radio-sensitizers for RT of cancer.83, 84 Therefore, coupled with their drug-loading capability and efficient photothermal effects, 2D TMDCs may become an\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nideal candidate for synergistic multiple treatment of cancer with better therapeutic efficacy which is going beyond monotherapy. 5) Low toxicity profile. To use the potential of 2D TMDCs in photothermal combination therapy, tremendous efforts should be dedicated in terms of evaluating their biosafety and toxicological issues.85, 86 On one hand, the toxicity of the whole formulation should be studied so as to minimize or even prevent unwanted side-effects. On the other hand, there should be an emphasis on the toxicity of 2D TMDCs themselves because they may show retention and accumulation in the tissues, which can cause chronic inflammatory reactions. Only demonstrating that 2D TMDCs are relatively non-toxic, they can be used in photothermal combination therapy. For example, it has been reported that MoS2 and WS2 possess relatively low cytotoxicity (lower than that of graphene) and genotoxicity,46-48 capability of biodegradation and rapid excretion in vivo,87 all of which them particularly suitable for further biomedical applications. 6) Easy-to-use preparation methods. It is an indispensable requirement for practical applications to develop simple and low-cost methods to obtain suspension of 2D TMDCs compatible with many biological systems. In this sense, both liquid-phase exfoliation (top-down approach) and hydro/solvothermal methods (bottom-up approach) are suitable for photothermal combination therapy.40, 88-90 Liquid-phase exfoliation method has been shown to yield the single-layer 2D TMDCs with good biocompatibility.40 A basic liquid-phase exfoliation method involves dispersion of the starting materials (layered TMDCs crystals) in an appropriate solvent, exfoliation via ultrasonication, and finally purification. Under normal circumstances, water, N-methyl pyrrolidone (NMP), dimethyl formamide (DMF), and the mixed solvents are used as solvents. Up to now, almost all 2D TMDCs such as MoS2, WS2, TiS2, TaS2, ZrS2, ReS2, MoSe2, WSe2 TaSe2, NbSe2, Sb2Se3, MoTe2, Bi2Te3, and NiTe2 have been synthesized by chemical exfoliation method.44, 90-92 Both Chou et al.66 and Yin et al.93 reported a simple approach based on ultrasonication of intercalated MoS2 powder. With this method, MoS2 dispersion with great colloidal stability and different sizes has been successfully prepared. To increase the yield of 2D TMDCs with small size, Yong et al.94 used ball milling method to cut the layered materials down to nanoscale sizes and then the nanoscale layered materials exfoliated by ultrasonication. On the other hand, hydro/solvothermal approach could obtain 2D TMDCs (such as WS2 and MoS2) with controlled shape, size and phases of the final samples. For this method, one of the advantages is to prevent 2D TMDCs from oxidizing; hence this method is favorable to prepare the 2D\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nTMDCs that can be easily oxidized. 7) Proper functionalization approaches. Surface chemistry is the key to enhance the dispersibility, stability, and biocompatibility of 2D TMDCs and control the interactions between these layered nanosheets and biocomponents, ultimately facilitating their behaviors in biological systems.40, 95-99 Depending on different application purposes, various surface functionalization strategies including covalent and non-covalent approaches can be designed to engineer the properties of 2D TMDCs for meeting the requirements of biological applications. The large surface area of 2D TMDCs makes them suitable for being modified with various polymers and surfactant through physical adsorption or chemical bonding (Table 1). For example, poly(acrylic acid) (PAA) and polyethylene glycol (PEG) could be coated onto the surface of WS2 via the relatively strong coordination interaction between carboxyl groups and tungsten atoms, aiming to improve their stability in water and physiological solutions.63 Alternatively, targeting moieties, such as folic acid (FA),100, 101 peptides,102, 103 and antibodies,103-105 may also be integrated with 2D TMDCs to enhance their targeting ability, so that they could be selectively taken up by cancer cells and then accumulated in tumor tissues. Moreover, many other inorganic nanostructures can also be integrated on the surface of 2D TMDCs to obtain nanocomposites with highly enriched functionalities.\nTable 1 Summary of the efforts on 2D TMDCs developed for photothermal combination therapy.\nTypes Materials Synthesis method Size (nm) Modification Therapeutic\nmodality Toxicity Ref.\nPTT/PDT\nMoS2 Lithium intercalation T: ~1 (AFM) LS: 100-1000 (DLS) PEG, Ce6 In vitro and in vivo Low 106 WS2 Liquid exfoliation T: ~1.6 (AFM) LS: 20-100 (TEM) BSA, MB In vitro Low 107 WSe2 Chemical exfoliation T: 4-5 (AFM) LS: ~210 (DLS) BSA, MB In vitro and in vivo Low 108\nPTT/\nChemotherapy\nMoS2 Liquid-phase exfoliation\nT: 0.8-1 (AFM) LS: ~80 (AFM)\nCS, DOX In vitro and in vivo Low 93\nMoS2 Chemical exfoliation T: ~1 (AFM) LS: ~120 (AFM)\nPEG, FA, DOX In vitro and in vivo Low 101\nMoS2 Solvothermal approach\nT: - LS: ~100 (TEM)\nPLGA, DOX In vitro and in vivo Low 109\nMoS2 Physical Ultrasonic exfoliation\nT: 5-15 (AFM) LS: ~89 (DLS)\nBSA, RV In vitro and in vivo Low 110\nWS2 Morrison method - Fe3O4, PEG, DOX\nIn vitro and in vivo Low 111\nPTT/RT\nWS2 Solution-phase method\nLS: 90-100 (DLS) Gd3+, PEG In vitro and in vivo Low 83\nWS2 Liquid exfoliation LS: ~3 (TEM, AFM) LA-PEG In vitro and in vivo Low 94 MoS2 Solvothermal method LS: ~300 (TEM) Bi2S3, PEG In vitro and in vivo Low 112 MoS2 Solvothermal method LS: ~5 (TEM) Polyaniline, PEG-NH2 In vitro and in vivo Low 113 Bi2Se3 One-step cation exchange method T: ~2.6 (TEM) LS: ~100 (TEM) FeSe2, PEG, 64Cu In vitro and in vivo Low 84 WS2 High-temperature LS: 80-150 (TEM) 188Re, PEG In vitro and in vivo Low 114\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nsolution method\nPTT/GT MoS2 Chemical exfoliation T: 1.5-2 (AFM) LS: ~200 (AFM)\nPEI, PEG, DNA In vitro Low 115\nWS2 Liquid exfoliation LS: ~3 (TEM) LA-PEI, siRNA In vitro and in vivo Low 116\nNotes: “T” represents for “thickness”; “LS” represents for “lateral size”. Abbreviation: Chlorin e6 (Ce6); Bovine serum albumin (BSA); Methylene Blue (MB); Chitosan (CS); Doxorubicin (DOX); Poly(lactic-co-glycolic acid) (PLGA); Resveratrol (RV); Lipoic acid (LA); Polyethylenimine (PEI); Gene therapy (GT); Atomic force microscope (AFM); Transmission electron microscope (TEM); Dynamic light scattering (DLS)."
    }, {
      "heading" : "3. 2D TMDC-assisted photothermal combination therapy",
      "text" : ""
    }, {
      "heading" : "3.1 Combination of Photothermal Therapy with Chemotherapy",
      "text" : "Chemotherapy, which employs drug for specific inhibition of cancer cells, has been clinically accepted and widely used as one of the main approaches for cancer treatment all over the world.117 However, it has been frequently observed that cancer cells show progressively diminishing response to drug over the course of chemotherapy as they acquire defense mechanisms against this change via expressing altered drug targets, enhancing self-repairing ability, increasing drug metabolism, or overexpressing drug efflux pumps.118, 119 To overcome the above-mentioned shortcomings as well as other limitations in current drugs such as insufficient water-solubility, instability, short circulation period, low selectivity, and nonspecific delivery, external stimulus-sensitive drug nanocarriers for cancer therapy has received tremendous attention.120 The sensitivity of oxygen-enriched cells to chemotherapy are higher than hypoxic cells, while the sensitivity to PTT are reversed.121 Hence, when combining PTT with chemotherapy, hyperthermia is capable of improving tumor sensitivity to anticancer drugs and the uptake rates of drugs, suppressing drug resistance, and increasing drug accumulation in tumor tissues, which are responsible for enhancing the therapeutic effect of chemotherapy.122-124 Besides, these two therapies could function synergistically, giving higher therapeutic efficacy (Fig. 3). Till now, we have endeavored to explore the new NIR photothermal-responsive drug delivery systems.82, 93, 125, 126 Our results indicated that compared with conventional drug carriers, nanocarriers with good photothermal ability can not only remarkably increase the drug accumulation at targeted cancer cells/tissues, but also drastically decrease the systemic toxicity, and even potentially avoid under- or over-dosing.82\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nFig. 3 Scheme of the NIR light-mediated nanoplatform for thermo-chemotherapy and optical imaging. (Reprinted with permission from ref. 127. Copyright 2013, Wiley-VCH).\nMost recently, the large surface area and high NIR absorbance of 2D TMDCs make them possible for a smart NIR light-induced photothermal-responsive drug-loading nanocarrier due to the two prominent advantages: i) realizing the on-demand drug release at desired site and time with controllable therapeutic outcome; and ii) exhibiting synergistic cancer therapy associated with hyperthermia and heat-induced drug release. Therefore, 2D TMDCs show great potential as a platform for the combination of PTT with chemotherapy, leading to the enhancement of the efficiency of chemotherapy. Yin et al.93 employed chitosan (CS) modified MoS2 nanosheets (MoS2-CS) as a chemotherapeutic drug nanocarrier to fabricate NIR-photothermal-triggered drug delivery carriers, facilitating the combination of chemotherapy and PTT into one system for cancer treatment (Fig. 4). Upon 808-nm NIR laser irradiation, non-covalently loaded doxorubicin (DOX) on MoS2-CS could be controllably released in a pH- and NIR-responsive manner. In vitro and in vivo tumor ablation studies demonstrated a better synergistic therapeutic effect when compared with either chemotherapy or PTT alone. Similarly, Wang et al.109 also reported that the PLGA-coated MoS2 could be used as a pH- and NIR-responsive nanocarrier to control the release of DOX. In vivo studies indicated that the generated heat upon NIR laser irradiation not only caused significant coagulation necrosis of tumor tissues but also enhanced the efficiency of tumor chemotherapy via triggering the fast release of encapsulated DOX molecules. To further improve the drug release, Yang et al.111 reported a coating of iron oxide pre-adsorbed WS2 with silica and PEG. Their results indicated that the release behavior of DOX from the obtained nanocomposite could respond to both pH and NIR laser. Moreover,\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nDOX release was particularly sensitive to NIR light within acidic environment. In vivo combined PTT/chemotherapy treatment of mice displayed a significant synergistic therapeutic effect superior to the respective mono-therapy.\nFig. 4 MoS2-based PTT/Chemotherapy combined therapy. (a) Schematic illustration of the high-throughput synthesis of MoS2-CS nanosheets as a NIR photothermal-triggered drug delivery system for efficient cancer therapy. (b) Cytotoxicity of KB cells treated with MoS2-CS with different concentrations, with or without irradiation (power = 1.0 W cm -2). (c) Tumor growth curves of tumors after various treatments for five groups. (d) Photograph of tumors from the control group, MoS2-CS group, DOX group, MoS2-CS+NIR group, and MoS2-CS-DOX+NIR group. (Reproduced with permission from ref. 93. Copyright 2014, American Chemical Society).\nTo further enable nanocarrier with specific cancer cell targeting ability, Liu et al.101 functionalized MoS2 nanosheets with FA-modified LA-PEG as a platform to load chemotherapy drugs, including DOX and 7-Ethyl-10-hydroxycamptothecin (SN38). The\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nhighest drug loading ratios (weight ratios between the drug and MoS2) at their tested conditions reached to ~239% for DOX and ~118% for SN38, which were much higher than that of porous nanostructures, and were comparable to that of graphene-based nanocomposites.128, 129 This outstanding loading ratio might be ascribed to the extraordinarily high surface area of MoS2 nanosheets and the strong interaction between MoS2 and drug molecules. As expected, quantitative flow cytometery data evidenced the targeting specificity. Moreover, it was found that DOX was released in a pH-responsive manner. Up to∼35% of DOX was released from MoS2-PEG@DOX over 24 h at pH 5.00 while only ∼10% of DOX release was observed at pH 7.40. After either intratumoral or intravenous administration, MoS2-PEG@DOX exhibited remarkable synergistic anti-cancer effects both in vitro and in vivo cancer treatment. The above results showed that NIR light photothermal-responsive platform provide a promising combinatorial strategy to improve cancer treatment and conquer the side-effects associated with chemotherapy."
    }, {
      "heading" : "3.2 Combination of photothermal therapy with photodynamic therapy",
      "text" : "Phototherapy, including PTT and PDT, has becoming a popular strategy for the treatment of cancers due to its various advantages such as low cost, highly localized and specific tumor treatment, and fewer side effects compared with traditional RT and chemotherapy. As mentioned above, PTT functions in a way to adopt photo-absorbing agents which possess the thermal conversion ability to transfer light energy into heat and then eradicate cancer cells by hyperthermia. While PDT applies the nontoxic photosensitizers (PSs) which can transfer the photo-energy to surrounding oxygen molecules for generating toxic reactive oxygen species (ROS), such as singlet oxygen (1O2), to kill nearby cancer cells. 107 The efficient generation of 1O2 requires an optimum incorporation of three key components: photosensitizer, light, and oxygen.130-133 However, tumor microenvironments are mostly hypoxic, which leads to low productivity of 1O2 and hence limits therapeutic efficacy. 134 To solve this problem, it is essential to combine PDT with PTT to develop a synergistic phototherapy, where PTT with hyperthermia may increase intratumoral blood flow which further transport more oxygen into cancer cells to improve PDT efficiency.135 Recently, several studies have reported that 2D TMDCs possess great potential as a simple but powerful nanoplatform for combined PTT/PDT treatment of cancer. For one thing, 2D TMDCs with high thermal conversion efficacy have ultra-high surface area due to their 2D structure, which endows them with the ability of interacting with PSs. For another, 2D\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nTMDCs are able to enhance PDT efficiency since hyperthermia increases cell membrane permeability and thus increase cellular uptake of PSs.75 In this process, 2D TMDCs not only produce significance heat upon NIR light irradiation for PTT but also act as photosensitizer carriers for PDT. Moreover, it has been demonstrated that 2D TMDCs such as MoS2 own better 1O2 production ability, 136 even than commercial photosensitizer protoporphyrin IX (PpIX).137 Therefore, 2D TMDCs have a potential as the candidates for synergistic therapy of PDT and PTT in cancer treatment. Yong et al.107 for the first time designed and fabricated bovine serum albumin (BSA)-coated WS2 nanosheets for in vitro PTT/PDT combined therapy of cancer. WS2 nanosheets were prepared by a facile and eco-friendly method using H2SO4 intercalation and then ultrasonication. Subsequently, the obtained WS2 nanosheets were modified with BSA to load methylene blue (MB) molecules which has a high photosensitizing efficacy and low dark toxicity. It is worthy to point out that, singlet oxygen generation (SOG) could be finely controlled via manipulating the MB release behavior from WS2 nanosheets using NIR irradiation. That is, the adsorption of MB on WS2 surface could efficiently inhibit of SOG due to the quenching ability of WS2 nanosheets; however, upon NIR irradiation, the heat could disturb MB interaction with WS2, MB fall off from WS2 surface, resulting in the efficient restoration of SOG for PDT application. This feature made WS2 nanosheets suitable for the controllable regulation of SOG, which might improve the efficacy and selectivity of PDT, and reduce the unwanted collateral damage to surrounding normal tissues. As expected, the in vitro results clearly showed that the efficacy of combined PDT/PTT therapy was significantly higher than those of PDT-only and PTT-only treatment, showing a synergistic anti-cancer effect. Furthermore, the first in vivo 2D TMDC-based PDT/PTT combined therapy in animal experiments was demonstrated by Liu et al.106 They designed a chlorin e6 (Ce6)-loaded MoS2-PEG (MoS2-PEG/Ce6) nanosheets for combinatorial PDT/PTT of cancer therapy, as shown in Fig. 5. By utilizing the ultra-high surface area of MoS2 nanosheets, Ce6 molecules photosensitizer were loaded on the surface of MoS2 nanosheets by physical adsorption. MoS2 nanosheets exhibit a higher Ce6 loading ratio (weight ratio of Ce6 to MoS2) (~30%) than PEGylated graphene oxide (~15%).138 The as-prepared MoS2-PEG/Ce6 could remarkably enhance intracellular delivery of Ce6 because mild hyperthermia is able to increase cell membrane permeability and significantly kill cancer cells when they are exposed to laser radiation with wavelengths at 808 nm (PTT effects) and 660 nm (PDT effects).\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nFig. 5 MoS2-based PTT/PDT combined therapy. (a) A scheme showing fabrication process of MoS2-PEG/Ce6 nanosheets for Ce6 loading and the combination of PTT and PDT. (b and c) Relative viabilities of 4T1 cells after incubation with free Ce6 or MoS2-PEG/Ce6 at various concentrations for 12 h and then treated without (b) or with (c) 660 nm light irradiation at 5 mW cm-2 for 30 min. (d) Relative viabilities of 4T1 cells after incubation with MoS2-PEG, free Ce6 or MoS2-PEG/Ce6 for various treatments. (e) Relative tumor volume curves of different groups of mice after the various treatments indicated. (f) Average body weight of mice after various treatments indicated. (Reproduced with permission from ref. 106. Copyright 2014, The Royal Society of Chemistry)."
    }, {
      "heading" : "3.3 Combination of Photothermal Therapy with Radiotherapy",
      "text" : "Radiotherapy (RT) employs ionizing radiation, including X-rays, gamma rays, and particle radiation, to kill tumor cells through induction of oxidative stress and/or breaking the DNA of the tumor cells.139, 140 Radiation can not only directly interact with cellular DNA to cause damage but also indirectly damage DNA by the free radicals. However, there are also some limitations of RT: (1) requirement of elevated doses and injury to the nearby normal tissue; (2) developed resistance to the radiation; (3) low efficiency for hypoxic cancer cells. Fortunately, hyperthermia could increase oxygen partial pressure and blood flow in and around tumor cells, resulting in enhanced the sensitivity of tumor to RT.141, 142 Besides, PTT can efficiently\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nkill the cancer cells that are not sensitive to RT.141, 143, 144 Hence, the combination of PTT and RT is a splendid approach to overcome the shortcomings existed in the RT alone treatment and eventually achieve a synergistic effect. There are two general paths for the enhancement of nanomaterial-enabled radiosensitization.145 The first is the improvement of the effectiveness of ionizing radiation, such as using high Z atom number element (e.g. W, Bi) contained nanomaterials with strong X-ray attenuation to increase energy deposition and promote the production of ROS (e.g. by radiolysis of water). The other is to make cells more susceptible to radiation by modulating cellular pathways and disturbing cellular homeostasis. For example, hyperthermia can not only directly kill tumor cells but also act as a sensitizer in radiation treatment.121 Heat can induce DNA double-strand breaks and cause protein aggregation to inhibit the repair of DNA damage especially in the case of ionizing radiation-induced DNA damage.146 So, 2D TMDCs (e.g. WS2, Bi2S3, Bi2Se3) with high photothermal conversion efficiency of NIR light and strong X-ray energy deposition, have great potential for the combination of PTT with RT, which integrate the two paths into one nanotheranostic. For example, Yong et al. fabricated PEG-functionalized WS2 (WS2-PEG) and explored the obtained nanocomposite as both radiosensitizer and photothermal adsorbing agent for combined PTT and RT (Fig. 6).94 The as-prepared WS2-PEG without any other component could produce significant heat upon 808 nm laser irradiation and simultaneously generate dose-enhancement effects of RT under X-ray irradiation. Upon intratumoral injection of WS2-PEG with NIR plus X-ray radiation, the most efficient tumor growth delay was achieved. Cheng et al.83 also reported the use of PEG-modified Gd-doped WS2 as a multifunctional agent for photothermal combination cancer treatment (WS2:Gd-PEG). In this nanostructure, the strong NIR absorbance of WS2 enables PTT and improve tumor oxygenation; W and Gd elements in the meantime could strongly attenuate X-ray irradiation to enhance ROS generation for improving RT treatment therapeutic effect. Their results exhibit that the combination of PTT and RT induced by WS2:Gd-PEG realized a remarkable synergistic effect to destroy cancer cells. These demonstrate that 2D TMDCs is a promising candidate for effective photothermal combination therapy to overcome the limitations of conventional RT. Later, Cheng et al.84 continued to construct a novel multifunctional 64Cu-labeled FeSe2/Bi2Se3-PEG nanostructure for multimodal image-guided photothermal-radiotherapy. Utilizing the intrinsic NIR and X-ray absorption properties of 64Cu-labeled FeSe2/Bi2Se3-PEG, they found that this nanostructure is able to realize the remarkable synergistic tumor destruction effect without causing obvious\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\ntoxicity to the treated animals. The mechanism of the synergistic RT/PTT effect of the three examples mentioned above was further confirmed by a DNA staining method (γ-H2AX staining).83, 84, 94 The levels of γ-H2AX foci (shown as red fluorescent spots) which correlate to the double-strand DNA breaking in the group of nanotheranostics (WS2-PEG, WS2:Gd-PEG, FeSe2/Bi2Se3-PEG) under X-ray irradiation, especially with NIR and X-ray irradiation, was the highest among all control groups. It is indicated that the strong X-ray attenuation ability element (W, Bi, Gd) contained 2D TMDCs can deposit X-ray irradiation energy and generate secondary and Auger electrons to damage DNA and inhibit cancer cell growth, and thus realize RT/PTT synergistic effect. In addition, Wang et al.112 utilized MoS2 as photothermal agent and Bi2S3 as radiation dose-enhancing agent to obtain MoS2/Bi2S3-PEG nanocomposite (MBP) with a good biocompatibility. The in vivo 4T1 mice model anti-tumor experiment was conducted by MBP intratumoral injection under laser and X-ray radiation. It is found that MBP showed a remarkable PTT efficiency as well as unique radiation enhancement effects. By viewing the four examples mentioned above from another perspective, 2D TMDCs (WS2, Bi2S3 or Bi2Se3) could act as a radiosensitizer to enhance external-beam radiation therapy (EBRT) by absorbing external X-ray beams. The use of external X-ray irradiation may produce side-effects. Alternatively, internal radioisotope therapy (RIT) have become another considerable radiation therapies. Chao et al.114 labeled a widely used radioisotope 188Re on PEGylated WS2 to construct a multifunctional nanotheranostics 188Re-WS2-PEG (Fig. 7). Tungsten element could absorb ionization radiation generated from 188Re without the need of external X-ray irradiation. The ‘‘self-sensitization” behavior of WS2 with better photothermal efficacy successfully enhanced the PTT/RT synergistic therapeutic effect. In conclusion, 2D TMDCs (e.g. WS2, Bi2S3 and Bi2Se3) show great advantage as a radiosensitizer both in X-ray-induced EBRT and radioisotope-induced RIT, making it possible for the clinic translation in the future.\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nFig. 6 WS2-based PTT and external-beam RT (EBRT) combined therapy. (a) Synthetic process diagram of WS2 quantum dots. (b) Representative fluorescence images of DNA fragmentation and nuclear condensation induced by WS2 QDs (100 ppm, 2 mL) and/or 808 nm laser lamp (1 W cm-2, 10 min) and/or X-ray radiation (6 Gy), stained with Hoechst and γ-H2AX for nuclear visualization and DNA fragmentation, respectively. (c) Corresponding normalized number of γ-H2AX after WS2 QDs (100 ppm, 2 mL) and/or 808 nm laser lamp (1 W cm-2, 10 min) and/or X-ray irradiation (6 Gy). (d) Average weight of tumors collected from each group of tumor-bearing mice after PTT and RT. (e) Photos of tumors collected from each group of the BEL-7402 tumor-bearing mice after various treatments. (Reproduced with permission from ref. 94. Copyright 2015, American Chemical Society). (f) Schematic illustration of the mechanism of 2D TMDCs-based PTT/RT combined therapy. (Reproduced with permission from ref. 112. Copyright 2015, Wiley-VCH).\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nFig. 7 WS2-based PTT and internal radioisotope therapy (RIT) combined therapy. (a) A scheme of synthesis and modification of WS2 nanoflakes and radiolabeling of 188Re. (b) Relative viabilities of 4T1 cells pretreated with different concentrations of WS2-PEG (0, 25, 50, and 100 µg mL-1) after incubated with free 188Re for 24 h. The RIT effect of free 188Re could be enhanced by WS2-PEG. (c) Relative viabilities of 4T1 cells incubated with WS2-PEG, free 188Re and 188Re-WS2-PEG with different concentrations for 24 h. (d) Relative tumor volumes after different treatments indicated including PBS control, WS2-PEG injection with laser irradiation, free 188Re injection, as well as 188Re-WS2-PEG injection without and with laser irradiation. (e) A scheme showing the proposed mechanism of enhanced 188Re-induced cancer cell killing by WS2-PEG. (Reproduced with permission from ref. 114. Copyright 2016, Wiley-VCH).\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3."
    }, {
      "heading" : "3.4 Combination of Photothermal Therapy with Gene Therapy",
      "text" : "The aim of gene therapy (GT) is to introduce therapeutic genetic materials (such as DNA or small interfering RNA) into cells to compensate for abnormal genes or produce a beneficial protein, and ultimately kill cancer cells.147 This process consists of three steps. Firstly, the extracellular therapeutic genetic materials should be effectively delivered into cells via endocytosis. Genes are then released from nanocarriers after being delivered from endosomes into cytosol. Finally, the therapeutic genetic materials interact with targeted mRNA, subsequently resulting in the silencing of a specific protein to achieve the aim of diseases treatment.8, 115, 148, 149 The first key factor involved in the process of GT is the loading efficiency of nanocarriers and the sensitivity of endosomal escape and gene release. Naked nucleic acids may not be suitable for GT because of their large size (~µm) and enzyme-induced degradation and/or inactivation. To solve this problem, either viral nanovectors or non-viral nanocarriers have been employed to deliver DNA or siRNA into cells.150 Unfortunately, the side-effects of viral nanovectors, such as endogenous virus recombination, oncogenic effects, unexpected immune response, and mutagenesis of host cell genes brought by viral vectors have aroused critical concerns.115, 150 Thus, non-viral gene delivery nanocarriers, such as polymer-, lipid-, and graphene-based systems, have been extensively explored over the past decades.151 Although the Food and Drug Administration (FDA) has not approved any non-viral gene delivery systems for GT,152, 153 recent progress of fundamental research associated with 2D TMDCs nanomaterials-based gene delivery systems has generated considerable advancement. Recently, due to the large surface area of 2D TMDCs, research efforts begin to be devoted to utilize them as the promising nanocarriers to load genetic materials, aiming to combine of PTT and GT to enhance the treatment efficiency. For example, Kou et al.150 designed a promising gene delivery system, that is, positively charged MoS2-PEG-PEI (polyethylenimine), which could bind to the negatively charged small interfering RNA (siRNA) by electrostatic interaction. Their results confirm that MoS2 could serve as a nanocarrier to gene delivery. The second key factor is how the 2D TMDCs-gene complex effectively escape from endosome and release gene. As demonstrated, photothermal-responsive 2D TMDC-based nanocarriers are capable of promoting escape from endosome and release gene. Taking MoS2 nanosheets as an example, they could convert NIR light into heat to stimulate escape and release due to the high NIR absorbance. Kim\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\ngroup115 successfully fabricated MoS2-PEI-PEG as a nanocarrier to load DNA by electrostatic interaction. When the nanocomposite entered endosome, the generated heat by MoS2-PEI-PEG under NIR irradiation could induce the endosomal escape of nanocomposite by local heat-mediated endosomal membrane rupture. Hydrophilic PEI and PEG linked with MoS2 via disulfide bond began to detach from MoS2 surface in a reducing environment. After endosomal escape, the intracellular reducing agent, glutathione (GSH) could further induce effective gene release (Fig. 8).\nFig. 8 Schematic illustration of sequential plasmid DNA delivery using MoS2-PEI-PEG nanocomposite by photothermally triggered endosomal escape followed by redox-mediated polymer detachment and DNA release. (Reprinted with permission from ref. 115. Copyright 2015, Wiley-VCH).\nUlteriorly, Zhang et al.116 deeply explored the combination mechanism of PTT with GT (Fig. 9). Hyperthermia can induce the synthesis and expression of heat shock protein 70\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\n(HSP70),154 which usually functions to enhance the resistance of cells to heat. Therefore, a pertinent strategy is introduced by GT to downregulate the expression of HSP70. They designed and constructed multifunctional WS2@polyetherimide (WS2@PEI) as a wonderful theranostic nanoplatform for gene-photothermal synergistic therapy of tumors at mild condition. WS2@PEI could be served as an efficient negative-charged survivin-siRNA carrier through the charge-charge interactions for GT. The in vitro experiment showed that no obvious cytotoxicity was observed both in BEL-7402 cells and HeLa cells by using cell counting kit-8 (CCK-8) assay and stronger cancer cells elimination ability was realized in the combination of GT and PTT. The cell death mechanism was that 808 nm laser irradiation increased the cell membrane permeability and thus enhanced survivin-siRNA transfection efficiency, leading to the silence of survivin protein and apoptosis of cancer cells. Furthermore, as expected, the in vivo results clearly showed that the antitumor efficacy of combined PTT/GT therapy was significantly higher than those of PTT-only and GT-only treatment. The nanocarrier WS2@PEI effectively delivered survivin-siRNA into cancer cells and obviously downregulated the protein expression level of HSP70 in the treatment of the combination of GT/PTT and upregulated its expression in the PTT alone group. The downregulation of HSP70 could improve cell sensitivity to heat at relative mild temperature, leading to the GT enhanced PTT antitumor synergistic effects. Besides, the combination of GT/PTT could efficiently suppress the relapse of tumor until the final of the experiment.\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nFig. 9 WS2-based PTT/GT combined therapy. (a) Schematic illustration of the design of WS2@PEI-siRNA in the improved PTT platform and dual-mode CT/PA imaging. (b) Photothermal effect of WS2@PEI-siRNA on BEL-7402 cells at an irradiation power intensity of 1 W cm-2. Cell viability after different treatments for 24 h. The protein expression levels of survivin and HSP70 of tumors from different groups are determined by Western Blot (c) and immunochemistry (d), respectively. (e) Tumor volume growth curves of mice after various treatments (four mice for each group). (f) Image of the harvested tumors from different groups of mice at the end of treatment. (Reproduced with permission from ref. 116. Copyright 2016, Wiley-VCH)."
    }, {
      "heading" : "3.5 Imaging-guided Therapy Based on 2D TMDCs",
      "text" : "Ideally, nanomaterial-based systems used in nanomedicine should have multimodality in both imaging and therapy. Precise temporal and spatial resolution to monitor therapeutic agents in vivo and predict the outcome of treatments is particularly required because it opens up a\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\npotential avenue to guide the therapeutic process, monitor the therapeutic response, avoid damage to surrounding healthy tissue, and finally eliminate the associated side effects.94 Owing to their intrinsic physical especially optical properties, 2D TMDCs can be not only used as a photothermal agent as well as a platform for combination of PTT with other treatments, but also applied in biomedical imaging (Fig. 10). On one hand, high NIR absorbance of the 2D TMDCs makes them ideal for photoacoustic (PA) imaging, which has become a new technology with the advantage of cross-sectional “listening” of entire tumors at depths not available to microscopy and sensitivity not available to computed tomography (CT) imaging.155-160 Liu et al.106 reported that prominent PA signals were seen in the tumor 24 h after i.v. injection of PEGylated MoS2. They found that PEGylated MoS2 mainly accumulated in the tumor. Chen et al.161 found that the photoacoustic effect of the MoS2 nanosheets is highly dependent on the number of layers. Single-layer MoS2 with excellent biocompatibility could produce stronger PA signals for highly sensitive detection of brain tumor cells than few-layer MoS2 and multi-layer MoS2. The reason of this interesting phenomenon is that the decreased layers of MoS2 can enhance the absorption of near-infrared light and change its elastic properties. PEGylated TiS2 162 and poly(vinylpyrollidone) (PVP) encapsulated Bi2Se3 nanosheets 163 could also be used as a contrast agent for PA imaging to identify the biodistribution and accumulation of nanotheronastics in the tumorous region (Fig. 11).\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nFig. 10 Multi-modal imaging-guided therapy based on 2D TMDCs. The insets of Optical imaging (Reproduced with permission from ref. 111. Copyright 2015, Elsevier); PA imaging (Reproduced with permission from ref. 162. Copyright 2014, The Royal Society of Chemistry); MRI imaging (Reproduced with permission from ref. 164. Copyright 2016, American Chemical Society); PET/SPECT imaging (Reproduced with permission from ref. 84. Copyright 2016, Wiley-VCH); CT imaging (Reproduced with permission from ref. 94. Copyright 2015, American Chemical Society).\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nFig. 11 The two mainly imaging modes (PA and CT) of represented 2D TMDCs. Photoacoustic (PA) imaging: (a) TiS2 (Reproduced with permission from ref. 162. Copyright 2014, The Royal Society of Chemistry); (b) MoS2 (Reproduced with permission from ref. 161. Copyright 2016, Wiley-VCH); (c) WS2 (Reproduced with permission from ref. 116. Copyright 2016, Wiley-VCH); (d) Bi2Se3 (Reproduced with permission from ref. 163. Copyright 2016, Wiley-VCH). Computed tomography (CT) imaging: (e) Bi2Se3 (Reproduced with permission from ref. 165. Copyright 2013, Wiley-VCH); (f) MoS2 (Reproduced with permission from ref. 113. Copyright 2016, American Chemical Society); (g) WS2 (Reproduced with permission from ref. 116. Copyright 2016, Wiley-VCH).\nIn addition, since 2D TMDCs containing high Z number atom such as W and Bi have high X-ray absorption coefficient, they are reported to be suitable candidates for CT imaging contrast agents to afford high-resolution 3D structural details of the whole body.94 For example, RABIN et al.166 and Li et al.167 reported that Bi2Se3 nanosheets showed excellent X-ray attenuation and could be utilized for enhanced X-ray CT imaging of tumor tissue in vivo. Alternatively, due to the presence of high Z number element W, BSA or PEG coated WS2 nanosheets were capable of generating stronger signals than commercial Iopromide or Iohexol, and could be employed as contrast agents for CT imaging of tumor tissues.107, 168 To note, no perfect single-mode imaging technology has been found till now. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT)\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nimaging show high sensitivity but low spatial resolution. Magnetic resonance imaging (MRI) owns high tissue resolution and unlimited detection depth but poor imaging sensitivity. Besides, one of the great disadvantages exist in optical imaging is the weak tissue penetration.169 Accordingly, multi-modal bio-imaging have become a blooming trend in the development of molecular imaging (Table 2). Dual-modal PA and X-ray CT imaging could be integrated into one system by utilizing the versatile properties of 2D TMDCs with high NIR and X-ray absorbance, so as to make full use of the advantages of deep penetration of CT imaging and spatial resolution of PA imaging. Yin et al. reported that MoS2 nanosheets can be used for dual-modal CT and PA imaging of tumor tissue in vivo.93, 170 Cheng et al.171 also explored PA and CT imaging behaviour of WS2-PEG nanosheets. Mice bearing 4T1 tumors were i.t. and i.v. injected with WS2-PEG nanosheets and imaged under a PA and CT imaging system. The strong PA signals and obviously enhanced contrast indicate the high tumor uptake and accumulation of WS2-PEG nanosheets.\nTable 2 The list of representative 2D TMDCs used for imaging-guided therapy.\nModality Image type Material Size (nm) Modification Therapeutic\nmodality Ref.\nSingle-modal\nPA\nTiS2 LS: ~100 (TEM) PEG PTT 162 MoS2 T: ~1 (AFM) LS: 100-1000 (DLS) PEG PTT/PDT 106 Bi2Se3 T: ~1.7 (AFM) LS: ~31.4 (TEM) PVP PTT 163\nCT\nWS2 - PEG-SH PTT 168 WS2 T: ~1.6 (AFM) LS: 20-100 (TEM) BSA PTT/PDT 107 Bi2Se3 T: ~3.9 (AFM) LS: ~90 (TEM) - PTT 167 MoS2 T: 0.8-1 (AFM) LS: ~80 (AFM) Chitosan, DOX PTT/Chemotherapy 93\nSPECT WS2 LS: ~80-150 (TEM) 188Re, PEG PTT/RT 114\nMulti-modal\nCT/PA WS2 T: ~1.1 (AFM) LS: 50-100 (TEM)\nPEG PTT 171\nCT/PA WS2 LS: ~3 (TEM, AFM) LA-PEG PTT/RT 94 CT/PA WS2 LS: ~3 (TEM) LA-PEI, siRNA PTT/GT 116 CT/PA MoS2 LS: ~5 (TEM) Polyaniline, PEG-NH2 PTT/RT 113 CT/PA MoS2 LS: ~300 (TEM) Bi2S3, PEG PTT/RT 112 PA/MRI MoS2 T: 8-12 (AFM) LS: ~100 (TEM) Fe3O4, PEG PTT 170 MRI/PA/PET MoS2 LS: 50-200 (TEM) 64Cu, Fe3O4, PEG PTT 172 FL/MRI/CT WS2 - Fe3O4, PEG, DOX PTT/Chemotherapy 111 PA/CT/MRI WS2 LS: 90-100 (DLS) Gd 3+, PEG PTT/RT 83 MRI/CT/PA/PET Bi2Se3 T: ~2.6 (TEM) LS: ~100 (TEM) FeSe2, PEG, 64Cu PTT/RT 84\nNotes: “T” represents for “thickness”; “LS” represents for “lateral size”.\nTo render more 2D TMDCs enriched functionalities, the functional moieties with other imaging capabilities can be decorated onto 2D TMDCs due to their high feasibility and easy-to-modify ability in surface chemistries. We successfully developed a simple two-step hydrothermal method to prepare superparamagnetic MoS2/Fe3O4 nanocomposites\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nfunctionalized with PEG and then employed it as photothermal as well as contrast agent in dual-modal PA and MR imaging.170 Yang et al. also reported that Fe3O4 nanoparticles could be non-covalently attached to the surface of WS2 to form WS2/Fe3O4 suspensions for multimodal PA and MR imaging of tumor tissues.111 Those two efforts demonstrated that Fe3O4 decorated MoS2 and WS2 could magnetically target to photothermal ablation of cancer indicated by PA and MR imaging. In addition, Cheng et al.83 prepared Gd doped-WS2 nanosheets that could be utilized for a combined PTT and RT of cancer under tri-modal (CT, PA and MRI) image guidance. The doped Gd ions could not only promote the contrast of WS2 sheets both in CT imaging and MRI, but also enhance the efficacy of RT. Cheng and co-workers further designed a novel multifunctional nano-probe based on a FeSe2/Bi2Se3 nanocomposite which was modified by PEG via hydrophobic interactions.84 Using its high NIR and X-ray absorbance, strong magnetic property as well as radioisotope labeling, multi-modal in vivo tumor imaging with 64Cu-FeSe2/Bi2Se3 was realized, including PA, CT, MR, and PET imaging. Besides, 64Cu-FeSe2/Bi2Se3 could also be used as a photothermal agent and radio-sensitizers for the combination of in vivo tumor PTT and RT. These examples demonstrate that versatile nanotheranostics based on 2D TMDCs have great potential in imaging-based diagnosis and provide a feasible platform for imaging guided therapy."
    }, {
      "heading" : "4. Toxicity and Biosafety",
      "text" : "The safety of nanomaterials is of great importance for their applications in the field of nanomedicine.99 2D TMDCs, similar to graphene nanosheets, possess layered structures and may not be easily bio-degraded in the living system. To understand the toxicology profiles of 2D TMDCs in vitro and in vivo, as well as their behaviors, is thus a critical fundamental question to be addressed in order to use this type of 2D TMDCs in biomedicine in the further. As 2D TMDCs have generated increasing attention in biomedical application, it is necessary to perform toxicological tests on them. To date, a variety of studies have been performed to evaluate the cytotoxicity of 2D TMDCs through cell counting kit (CCK), water-soluble tetrazolium salt (WST-8) or methylthiazolyldiphenyl-tetrazolium bromide (MTT) assays. Most of the results indicated that 2D TMDCs were non-cytotoxic within a certain range of concentrations (Table 1). On one hand, the cytotoxicity may vary with the different synthesis methods and situations.173 For example, Appel et al.46 demonstrated that, through a series of biocompatibility tests, pristine 2D TMDCs (ME-WS2, ME-MoS2 and CVD MoS2) did not induce the decrease of cellular viability or genetic defects, which paved a way for the use of 2D ME-WS2,\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nME-MoS2 and CVD MoS2 in future application of medical devices. Chng et al. 174 reported that the cytotoxicity of MoS2 nanosheets was influenced by the extent of exfoliation. Their results revealed that MoS2 nanosheets exfoliated with t-Bu-Li and n-Bu-Li (more efficient at exfoliating MoS2 than Me-Li) were significantly more cytotoxic than Me-Li exfoliated nanosheets. That is to say, MoS2 exhibits stronger toxicity with increased exfoliation. Liu et al. 101 carefully studied the MoS2 nanosheets with and without functionalization. The results showed that pristine MoS2 nanosheets could induce slight cytotoxicity after culturing for 3 days; while MoS2 nanosheets functionalized with PEG exhibited insignificant cytotoxicity. They further assessed the intracellular ROS levels in MoS2 treated cells using the dihydroethidine probe. Compared with the MTT assay, no significant increase on the percentage of dihydroethidine (DHE) positive cells was observed in cells treated with MoS2, suggesting minimal oxidative stress induced by those nanosheets. Moreover, the research of Shi group demonstrated that PEGylated MoS2 nanosheets showed no significant cytotoxicity at a series of concentrations, even up to 500 µg mL-1.175 On the other hand, the cytotoxicity may vary with different compounds. The study of Pumera group47, 176 indicated that MoS2 and WS2 induced very low toxicity to the lung cancer cells (A549 cells) even at high concentration (400 µg mL-1), while WSe2 exhibited greater toxicity compared with MoS2 and WS2. They also found that TMDCs exhibited lower toxicity than GO with the same testing the same assay even though the tested concentration of MoS2 and WS2 (200 µg mL -1) nanosheets was 1.6 times higher than that of GO (125 µg mL-1) nanomaterials (Fig. 12). Additionally, Pumera group subsequently compared the toxicological behavior of TMDCs materials associated with different transition metal element (Vanadium) as well as the chalcogen type.177 As shown in Fig. 12, comparatively speaking, both in MTT and WST-8 assay, the toxicity profile of VS2 is consistently higher than that of MoS2 and WS2 in almost all tested concentration groups. The similar phenomenon was also observed in the selenides. It means that TMDCs which contains the vanadium element is intrinsically more toxic than molybdenum and tungsten. They also preliminarily noticed that the metal selenides and tellurides showed a higher toxicity compared to the corresponding metal sulfides.\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nFig. 12 Toxicity and Biosafety of 2D TMDCs. (a) Overall cell viabilities of different control materials and different TMDCs at as a function of time. (Reprinted with permission from ref. 46. Copyright 2016, American Chemical Society). (b) Cytotoxicity assessment following a 24 h exposure to various concentrations of bulk MoS2 and after exfoliation with methyllithium (Me-Li), n-butyllithium (n-Bu-Li) and tert-butyllithium (t-Bu-Li). Cell viability of the human lung carcinoma epithelial cells was determined using MTT assay. (Reprinted with permission from ref. 174. Copyright 2014, The Royal Society of Chemistry). (c) Normalized percentage of viable cells measured using MTT/WST-8 assays, after 24 h exposure with either GO (125 mg mL-1) synthesized using the Hoffmann (GO-HO) and Hummers method (GO-HU), or 200 mg mL-1 of chlorine-doped graphene (Cl-TRGO), iodine-doped graphene (I-TRGO), and exTMDs. (Reproduced with permission from ref. 47. Copyright 2014, Wiley-VCH). (d) Comparison of cytotoxicity data between various exfoliated Group V and Group VI transition metal dichalcogenides (i.e.: MoS2, WS2, WSe2, VS2, VSe2, VTe2) for MTT and WST-8 assay. (Reproduced with permission from ref. 177. Copyright 2016, Wiley-VCH). (e) A scheme showing the different pathways of the clearance of MS2-PEG nanosheets (M = Mo, W, and Jo\nur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nTi). (Reproduced with permission from ref. 87. Copyright 2016, Wiley-VCH).\nAlternatively, the toxicity profiles of 2D TMDCs performed in vivo was also assessed through animal studies. Many groups have reported that the 2D TMDCs treated mice could survive for more than one month without any apparent adverse effects to their health. For example, Qian et al.162 showed that after i.v. injection of PEGylated TiS2 nanosheets, no mouse death or any sign of toxic effect was observed within 60 days. Liu et al. also carried out a pilot study to assess the in vivo toxicity of MoS2 functionalized with PEG. 101 After 1, 7, 15, and 30 days post-injection, the blood of female Balb/c mice were collected. The results of both serum biochemistry assay and complete blood panel test were rather close to those of untreated healthy mice, suggesting that MoS2-PEG was not noticeably toxic to mice. Deeply, the long-term biodistribution, excretion, and toxicity of PEGylated MS2 (M=Mo, W, Ti) were systematically investigated after i.v. injection.87 Notably, the PEGylated 2D TMDCs mainly accumulated in reticuloendothelial systems (RES) organs, such as liver and spleen, at 1 day post injection. Interestingly, in marked contrast to WS2-PEG and TiS2, which retained in the RES for months, MoS2-PEG could be degraded and excreted almost completely by urine and feces. Degradation experiments indicate that MoS2-PEG could be oxidized into colorless water-soluble MoVI-oxide species (such as MoO4 2-) to allow its clearance from the body, and TiS2-PEG were hard to be completely excreted from the mouse body due to the formation of water-insoluble TiO2 aggregates (Fig. 12). Different from MoS2-PEG and TiS2-PEG, WS2-PEG was more stable and thus was hardly oxidized, ultimately resulting in much longer in vivo retention. Moreover, the results of histological and blood analysis suggested that these three types of 2D TMDCs have no obvious long-term toxicity at the tested dose. Zhang et al. 165 also investigated 90-day long term in vivo biodistribution and toxicity of Bi2Se3 nanoplates. Those experiments demonstrate that PVP modified Bi2Se3 with very low liver toxicity even at a 20 mg kg-1 dose did not cause significant infection and inflammation and 93% of it could be cleared during the whole treatment period."
    }, {
      "heading" : "5. Conclusions and Future Outlook",
      "text" : "Development of 2D TMDCs for the photothermal-based combined therapy of cancers is of great significance. 2D TMDCs such as MoS2 and WS2 have been extended to a large range of applications due to their special physical and chemical properties, and also have achieved great success in the field of nanomedicine. In this review, we briefly summarized the recent\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nprogress of 2D TMDCs in anti-tumor photothermal-based combination therapy. Moreover, various inorganic nanoparticles such as Fe3O4 could be anchored on the surface of 2D TMDCs, endowing 2D TMDCs-based nanocomposites multimodal imaging and imaging guided therapy. At the same time, toxic effects induced by 2D TMDCs was discussed so as to provide some available information to properly evaluate their effects on human and environmental health and safety. It is well known that the challenges and obstacles still exist in the road of the translation of nanotheranostics into medicine.178-183 Therefore, in the near further, there will be a large number of research areas that are particularly promising. Here we summarize the significant aspects of the challenges for the field. First, standardization of the methods for the preparation of 2D TMDCs nanomaterials. It is well known that different preparation methods will lead to the different physical, chemical, and biological properties, such as crystallinity, size, optical electrical properties, and biocompatibility, which largely impact their penetration ability, cytotoxicity, and even therapeutic effect. For example, as mentioned before, MoS2 exhibits stronger toxicity with increased exfoliation.174 Thus, it is necessary to establish a standardization for the preparation of 2D TMDCs with similar physical and chemical properties, favoring the study of the relationship between therapeutic effect and properties of 2D TMDCs. Second, establishment of proper functionalization techniques. The surface of 2D TMDCs plays a significant role in controlling their toxicity, biodegradability, bioavailability, as well as bioconjugation with biomolecules. The general requirements that meet the applications for the combined therapy of cancer mainly include: i) 2D TMDCs require a biocompatible and hydrophilic surface to make a stable dispersion in water and physiological solutions; ii) 2D TMDCs need reactive functional groups on their surface for subsequent bioconjugation to various biomolecules (such as peptides, antibodies, and aptamers) for targeting a specific site in the body. Therefore, it is important to employ proper and nontoxic functionalization methods to modify the surface property for bioapplications in living systems. Third, enrichment of the combined therapeutic modalities. The single anti-tumor treatment based on 2D TMDCs mainly focuses on PTT, which fully utilize their intrinsic property of good photothermal conversion ability. But the efficiency of single photothermal treatment is not high enough to kill cancers in clinical. Therefore, rationally developing combined therapy based on PTT is of great significance in anti-tumor treatment. Moreover, imaging-guided photothermal-based therapy plays a double function of both diagnosis and treatment. However, recent researches based on imaging-guided combined therapy only focus on few\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\n2D TMDCs, such as MoS2, WS2, which severely limits the application of the entire class of 2D TMDCs in the field of biomedicine. Hence, it is of significant importance to expand the combined therapeutic modalities and further develop imaging-guided combined therapy technology to provide more valuable information for clinical and tumor early discovery and therapy.\nFourth, explanation of the mechanisms of photothermal combination therapy. Photothermal combination therapy has numerous applications in the field of cancer treatment, and numerous efforts have been devoted to explain the corresponding mechanisms. However, until now, the available mechanisms are still not fully understood and a generalized standard for determining an optimal hyperthermia modality combined with other therapeutic techniques has not been established. Therefore, further investigations are merited to understand the synergistic cellular and molecular mechanism. Fifth, establishment of evaluation criteria for the combined therapy. According to the research work mentioned above in this review, multifunctional 2D TMDCs applied in tumor diagnosis and combined therapy exhibit good effects and could reach synergistic therapeutic effects both in cell cytotoxicity tests and/or animal model experiments. However, an existing aporia that restricts them from the bench to bedside is the lack of a reasonable evaluation criteria to measure the therapeutic effect of different 2D TMDCs in different cell cytotoxicity tests and/or animal model experiments. Sixth, Toxicology of 2D TMDCs. Sharifi et al.184 discussed that toxicity of nanomaterials is closely connected with physicochemical properties, such as size, surface chemistry, shape, protein absorption gradient and surface smoothness or roughness. Fischer et al.185 emphasized the need for in vivo studies to accurately assess nanotoxicity since most reported nanotoxicity studies in vitro cell culture are not correspondent to in vivo results. Currently, although in vivo deposition and clearance of 2D TMDCs have been studied in some efforts, it is still difficult to evaluate and compare the toxicity of the entire class of 2D TMDCs, and there is little information on their in vivo metabolic process and whether it can be degraded or not. Moreover, the studies on the long-term consequences of nanomaterials on human health and the mechanism of toxicity are still acutely insufficiency. Therefore, with increasing numbers of drugs, therapeutic agents and imaging contrast agents based on nanomaterials, it is of significance to take the long-term biosafety into account when 2D TMDCs nanomaterials enters the body. TMDCs-induced immunotoxicity also has become a challenge and need to be evaluated for future biomedical application.186, 187\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nAs the Chinese saying goes: the way ahead is long and has no ending; yet high and low I’ll search with my will unbending. To use 2D TMDCs as biomedicine for the treatment of cancer, more efforts need to be undertaken to make them truly beneficial for human beings.\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nList of abbreviations\n2D Two-dimensional 2D TMDCs Two-dimensional transition metal dichalcogenides AFM BN Atomic force microscope Boron nitride BP Black phosphorus BSA CCK Bovine serum albumin Cell counting kit Ce6 Chlorin e6 Cl-TRGO Chlorine-doped graphene CS Chitosan CT Computed tomography CVD Chemical vapor deposition DHE Dihydroethidine DMF Dimethyl formamide DLS DOX Dynamic light scattering Doxorubicin EBRT External-beam radiation therapy FA Folic acid FDA Food and Drug Administration g-C3N4 Graphitic carbon nitride GO Graphene oxides GO-HO Graphene oxides synthesized using the Hoffmann method GO-HU Graphene oxides synthesized using the Hummers method GSH Glutathione GT Gene therapy HSP70 Heat shock protein 70 I-TRGO Iodine-doped graphene LA Lipoic acid MB Methylene blue MBP MoS2/Bi2S3-PEG MDR Multi-drug resistance ME Mechanically exfoliated Me-Li MTT Methyllithium Methylthiazolyldiphenyl-tetrazolium bromide MRI Magnetic resonance imaging n-Bu-Li n-butyllithium NIR Near-infrared NMP N-methyl pyrrolidone PA Photoacoustic PAA Poly(acrylic acid) PDT Photodynamic therapy PEG Polyethylene glycol PEI Polyethylenimine PET Positron emission tomography PLGA Poly(lactic-co-glycolic acid) PpIX Protoporphyrin IX\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3.\nPSs Photosensitizers PTT Photothermal therapy PVP Poly(vinylpyrollidone) RES Reticuloendothelial systems RIT Radioisotope therapy ROS Reactive oxygen species RT Radiotherapy RV Resveratrol siRNA Small interfering RNA SN38 7-Ethyl-10-hydroxycamptothecin SOG Singlet oxygen generation SPECT Single-photon emission computed tomography t-Bu-Li TEM WST-8 Tert-butyllithium Transmission electron microscope water-soluble tetrazolium salt"
    }, {
      "heading" : "Acknowledgments",
      "text" : "This work was supported by the National Basic Research Programs of China (2016YFA0201600, 2016YFA0202104 and 2015CB932104) and National Natural Science Foundation of China (Nos. 31571015, 11621505, 11435002 and 21320102003).\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 7\nFe br\nua ry\n2 01\n7. D\now nl\noa de\nd by\nU N\nIV E\nR SI\nT Y\nO F\nN E\nB R\nA SK\nA o\nn 07\n/0 2/\n20 17\n1 3:\n40 :2\n3."
    } ],
    "references" : [ {
      "title" : "J",
      "author" : [ "X. Wang", "L. Yang", "Z. Chen", "D.M. Shin", "CA. Cance" ],
      "venue" : "Clin.,",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "J",
      "author" : [ "A.S. Thakor", "S.S. Gambhir", "CA. Cance" ],
      "venue" : "Clin.,",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Chem",
      "author" : [ "G. Chen", "I. Roy", "C. Yang", "P.N. Prasad" ],
      "venue" : "Rev.,",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "E.K. Lim", "T. Kim", "S. Paik", "S. Haam", "Y.M. Huh", "K. Lee" ],
      "venue" : "Rev.,",
      "citeRegEx" : "4",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Z",
      "author" : [ "S. Mitragotri", "D.G. Anderson", "X. Chen", "E.K. Chow", "D. Ho", "A.V. Kabanov", "J.M. Karp", "K. Kataoka", "C.A. Mirkin", "S.H. Petrosko", "J. Shi", "M.M. Stevens", "S. Sun", "S. Teoh", "S.S. Venkatraman", "Y. Xia", "S. Wang" ],
      "venue" : "Gu and C. Xu, ACS Nano,",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Sci",
      "author" : [ "E.K.-H. Chow", "D. Ho" ],
      "venue" : "Transl. Med.,",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Ther",
      "author" : [ "C.M. Hu", "S. Aryal", "L. Zhang" ],
      "venue" : "Deliv.,",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Adv",
      "author" : [ "G. Tian", "X. Zhang", "Z. Gu", "Y. Zhao" ],
      "venue" : "Mater.,",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and W",
      "author" : [ "C. He", "C. Chan", "R.R. Weichselbaum", "G.F. Fleming", "S.D. Yamad" ],
      "venue" : "Lin, EBioMedicine,",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Trends Mol",
      "author" : [ "X. Xu", "W. Ho", "X. Zhang", "N. Bertrand", "O. Farokhzad" ],
      "venue" : "Med.,",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "C",
      "author" : [ "P. Boisseau", "B. Loubaton" ],
      "venue" : "R. Phys.,",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Polym",
      "author" : [ "Y. Zhang", "C. Ang", "Y. Zhao" ],
      "venue" : "J.,",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and W",
      "author" : [ "F. Che" ],
      "venue" : "Cai, Nanomedicine,",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Cancer Res",
      "author" : [ "J. Wang", "J. Qiu" ],
      "venue" : "Front.,",
      "citeRegEx" : "14",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and S",
      "author" : [ "Q. Chen", "J. Wen", "H. Li", "Y. Xu", "F. Li" ],
      "venue" : "Sun, Biomaterials,",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "K. Yang", "L. Feng", "X. Shi", "Z. Liu" ],
      "venue" : "Soc. Rev.,",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Expert Opin",
      "author" : [ "K. Yang", "L. Feng", "Z. Liu" ],
      "venue" : "Drug Deliv.,",
      "citeRegEx" : "17",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Ther",
      "author" : [ "S.C. Patel", "S. Lee", "G. Lalwani", "C. Suhrland", "S.M. Chowdhury", "B. Sitharaman" ],
      "venue" : "Deliv.,",
      "citeRegEx" : "18",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Adv",
      "author" : [ "L. Feng", "L. Wu", "X. Qu" ],
      "venue" : "Mater.,",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Adv",
      "author" : [ "D. Bitounis", "H. Ali-Boucetta", "B.H. Hong", "D.H. Min", "K. Kostarelos" ],
      "venue" : "Mater.,",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Chem",
      "author" : [ "H.Y. Mao", "S. Laurent", "W. Chen", "O. Akhavan", "M. Imani", "A.A. Ashkarran", "M. Mahmoudi" ],
      "venue" : "Rev.,",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and Z",
      "author" : [ "K. Yang", "S. Zhang", "G. Zhang", "X. Sun", "S.T. Le" ],
      "venue" : "Liu, Nano Lett.,",
      "citeRegEx" : "22",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and Z",
      "author" : [ "H. Shen", "L. Zhang", "M. Li" ],
      "venue" : "Zhang, Theranostics,",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Chem",
      "author" : [ "P.T. Yin", "S. Shah", "M. Chhowalla", "K.B. Lee" ],
      "venue" : "Rev.,",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and L",
      "author" : [ "M. Orecchioni", "R. Cabizza", "A. Bianc" ],
      "venue" : "G. Delogu, Theranostics,",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and W",
      "author" : [ "Y. Zhang", "T.R. Nayak", "H. Hon" ],
      "venue" : "Cai, Nanoscale,",
      "citeRegEx" : "26",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and H",
      "author" : [ "W. Zhang", "Z. Guo", "D. Huang", "Z. Liu", "X. Gu" ],
      "venue" : "Zhong, Biomaterials,",
      "citeRegEx" : "27",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Adv",
      "author" : [ "R. Kurapati", "K. Kostarelos", "M. Prato", "A. Bianco" ],
      "venue" : "Mater.,",
      "citeRegEx" : "28",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and J",
      "author" : [ "S.Z. Butler", "S.M. Hollen", "L. Cao", "Y. Cui", "J.A. Gupta", "H.R. Gutierrez", "T.F. Heinz", "S.S. Hong", "J. Huang", "A.F. Ismach", "E. Johnston-Halperin", "M. Kuno", "V.V. Plashnitsa", "R.D. Robinson", "R.S. Ruoff", "S. Salahuddin", "J. Shan", "L. Shi", "M.G. Spencer", "M. Terrones", "W. Wind" ],
      "venue" : "E. Goldberger, ACS Nano,",
      "citeRegEx" : "29",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Acc",
      "author" : [ "R. Lv", "J.A. Robinson", "R.E. Schaak", "D. Sun", "Y. Sun", "T.E. Mallouk", "M. Terrones" ],
      "venue" : "Chem. Res.,",
      "citeRegEx" : "30",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Adv",
      "author" : [ "W. Chen", "J. Ouyang", "H. Liu", "M. Chen", "K. Zeng", "J. Sheng", "Z. Liu", "Y. Han", "L. Wang", "J. Li", "L. Deng", "Y.N. Liu", "S. Guo" ],
      "venue" : "Mater.,",
      "citeRegEx" : "31",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and G",
      "author" : [ "G.G. Gench" ],
      "venue" : "Ciofani, Nanomedicine,",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and D",
      "author" : [ "Q. Weng", "B. Wang", "X. Wang", "N. Hanagata", "X. Li", "D. Liu", "X. Wang", "X. Jiang", "Y. Band" ],
      "venue" : "Golberg, ACS Nano,",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Chem",
      "author" : [ "T. Lu", "L.B. Wang", "Y. Jiang", "Q.W. Liu", "C.J. Huang", "J. Mater" ],
      "venue" : "B,",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and C",
      "author" : [ "R. Chen", "J. Zhang", "Y. Wang", "X. Chen", "J.A. Zapie" ],
      "venue" : "S. Lee, Nanoscale,",
      "citeRegEx" : "35",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Chem",
      "author" : [ "L.S. Lin", "Z.X. Cong", "J. Li", "K.M. Ke", "S.S. Guo", "H.H. Yang", "G.N. Chen", "J. Mater" ],
      "venue" : "B,",
      "citeRegEx" : "36",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and H",
      "author" : [ "Y. Dong", "Q. Wang", "H. Wu", "Y. Chen", "C.H. Lu", "Y. Ch" ],
      "venue" : "H. Yang, Small,",
      "citeRegEx" : "37",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Y",
      "author" : [ "H. Li" ],
      "venue" : "Shi, M.-H. Chiu and L.-J. Li, Nano Energy,",
      "citeRegEx" : "38",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and M",
      "author" : [ "H. Tian", "M.L. Chin", "S. Najmaei", "Q. Guo", "F. Xia", "H. Wan" ],
      "venue" : "Dubey, Nano Res.,",
      "citeRegEx" : "39",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Adv",
      "author" : [ "K. Kalantar-zadeh", "J.Z. Ou", "T. Daeneke", "M.S. Strano", "M. Pumera", "S.L. Gras" ],
      "venue" : " Page 39 of 47  Journal of Materials Chemistry B Jo  ur  na  lo  fM  at  er  ia  ls  C  he  m  is  tr  y  B  A  cc  ep  te  d  M  an  us  cr  ip  t Pu  bl  is  he  d  on  0  7  Fe  br  ua  ry  2  01 7.  D  ow  nl  oa  de  d  by  U  N  IV  E  R  SI  T  Y  O  F  N  E  B  R  A  SK  A  o  n  07  /0  2/  20  17  1  3:  40  :2 3.  View Article Online DOI: 10.1039/C7TB00195A  40  Funct. Mater.,",
      "citeRegEx" : "40",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Acta Chim",
      "author" : [ "T. Liu", "L. Cheng", "Z. Liu" ],
      "venue" : "Sin.,",
      "citeRegEx" : "41",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and H",
      "author" : [ "Y. Chen", "Y. Wu", "B. Sun", "S. Li" ],
      "venue" : "Liu, Small,",
      "citeRegEx" : "42",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Chem",
      "author" : [ "M. Xu", "T. Liang", "M. Shi", "H. Chen" ],
      "venue" : "Rev.,",
      "citeRegEx" : "43",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nat",
      "author" : [ "M. Chhowalla", "H.S. Shin", "G. Eda", "L.J. Li", "K.P. Loh", "H. Zhang" ],
      "venue" : "Chem.,",
      "citeRegEx" : "44",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nat",
      "author" : [ "Q.H. Wang", "K. Kalantar-Zadeh", "A. Kis", "J.N. Coleman", "M.S. Strano" ],
      "venue" : "Nanotechnol.,",
      "citeRegEx" : "45",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Sci",
      "author" : [ "J.H. Appel", "D.O. Li", "J.D. Podlevsky", "A. Debnath", "A.A. Green", "Q.H. Wang", "J. Chae", "ACS Biomater" ],
      "venue" : "Eng.,",
      "citeRegEx" : "46",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "W.Z. Teo", "E.L. Chng", "Z. Sofer", "M. Pumera" ],
      "venue" : "Eur. J.,",
      "citeRegEx" : "47",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and Z",
      "author" : [ "T. Liu", "Y. Chao", "M. Gao", "C. Liang", "Q. Chen", "G. Song", "L. Chen" ],
      "venue" : "Liu, Nano Res.,",
      "citeRegEx" : "48",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "C. Tan", "H. Zhang" ],
      "venue" : "Soc. Rev.,",
      "citeRegEx" : "49",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "in Chemical Modelling: Volume 11, eds",
      "author" : [ "A. Kuc" ],
      "venue" : "M. Springborg and J.-O. Joswig, The Royal Society of Chemistry,",
      "citeRegEx" : "50",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and J",
      "author" : [ "A.V. Kolobo" ],
      "venue" : "Tominaga, in Two-Dimensional Transition-Metal Dichalcogenides, Springer International Publishing, Cham,",
      "citeRegEx" : "51",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Acc",
      "author" : [ "W. Zhao", "R.M. Ribeiro", "G. Eda" ],
      "venue" : "Chem. Res.,",
      "citeRegEx" : "52",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Chem",
      "author" : [ "X. Zhang", "X.F. Qiao", "W. Shi", "J.B. Wu", "D.S. Jiang", "P.H. Tan" ],
      "venue" : "Soc. Rev.,",
      "citeRegEx" : "53",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Chem",
      "author" : [ "X. Chia", "A.Y. Eng", "A. Ambrosi", "S.M. Tan", "M. Pumera" ],
      "venue" : "Rev.,",
      "citeRegEx" : "54",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and M",
      "author" : [ "R. Lv", "H. Terrones", "A.L. Elias", "N. Perea-Lopez", "H.R. Gutierrez", "E. Cruz-Silva", "L.P. Rajukumar", "M.S. Dresselhau" ],
      "venue" : "Terrones, Nano Today,",
      "citeRegEx" : "55",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Philos",
      "author" : [ "M.K. Jana", "C.N.R. Rao" ],
      "venue" : "Trans. R. Soc. A,",
      "citeRegEx" : "56",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Acc",
      "author" : [ "M.A. Pimenta", "E. Del Corro", "B.R. Carvalho", "C. Fantini", "L.M. Malard" ],
      "venue" : "Chem. Res.,",
      "citeRegEx" : "57",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Angew",
      "author" : [ "Z. Zeng", "Z. Yin", "X. Huang", "H. Li", "Q. He", "G. Lu", "F. Boey", "H. Zhang" ],
      "venue" : "Chem. Int. Ed. Engl.,",
      "citeRegEx" : "58",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Nat",
      "author" : [ "B. Radisavljevic", "A. Radenovic", "J. Brivio", "V. Giacometti", "A. Kis" ],
      "venue" : " Page 40 of 47  Journal of Materials Chemistry B Jo  ur  na  lo  fM  at  er  ia  ls  C  he  m  is  tr  y  B  A  cc  ep  te  d  M  an  us  cr  ip  t Pu  bl  is  he  d  on  0  7  Fe  br  ua  ry  2  01 7.  D  ow  nl  oa  de  d  by  U  N  IV  E  R  SI  T  Y  O  F  N  E  B  R  A  SK  A  o  n  07  /0  2/  20  17  1  3:  40  :2 3.  View Article Online DOI: 10.1039/C7TB00195A  41  Nanotechnol.,",
      "citeRegEx" : "59",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and C",
      "author" : [ "U. Gupta", "B.S. Naidu", "U. Maitra", "A. Singh", "S.N. Shirodkar", "U.V. Waghmar" ],
      "venue" : "N. R. Rao, APL Mater.,",
      "citeRegEx" : "60",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Mater",
      "author" : [ "N. Wang", "F. Wei", "Y. Qi", "H. Li", "X. Lu", "G. Zhao", "Q. Xu", "ACS Appl" ],
      "venue" : "Interfaces,",
      "citeRegEx" : "61",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Chem",
      "author" : [ "Y. Chen", "C. Tan", "H. Zhang", "L. Wang" ],
      "venue" : "Soc. Rev.,",
      "citeRegEx" : "63",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and Y",
      "author" : [ "G. Yang", "C. Zhu", "D. Du", "J. Zh" ],
      "venue" : "Lin, Nanoscale,",
      "citeRegEx" : "64",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "TrAC Trends Anal",
      "author" : [ "M. Pumera", "A.H. Loo" ],
      "venue" : "Chem.,",
      "citeRegEx" : "65",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Angew",
      "author" : [ "S.S. Chou", "B. Kaehr", "J. Kim", "B.M. Foley", "M. De", "P.E. Hopkins", "J. Huang", "C.J. Brinker", "V.P. Dravid" ],
      "venue" : "Chem. Int. Ed.,",
      "citeRegEx" : "66",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and L",
      "author" : [ "L. Yuwen", "J. Zhou", "Y. Zhang", "Q. Zhang", "J. Shan", "Z. Luo", "L. Weng", "Z. Ten" ],
      "venue" : "Wang, Nanoscale,",
      "citeRegEx" : "67",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and L",
      "author" : [ "Q. Liu", "C. Sun", "Q. He", "A. Khalil", "T. Xiang", "D. Liu", "Y. Zhou", "J. Wan" ],
      "venue" : "Song, Nano Res.,",
      "citeRegEx" : "68",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Adv",
      "author" : [ "D. Chimene", "D.L. Alge", "A.K. Gaharwar" ],
      "venue" : "Mater.,",
      "citeRegEx" : "69",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Adv",
      "author" : [ "B.L. Li", "J. Wang", "H.L. Zou", "S. Garaj", "C.T. Lim", "J. Xie", "N.B. Li", "D.T. Leong" ],
      "venue" : "Funct. Mater.,",
      "citeRegEx" : "70",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and L",
      "author" : [ "X. Li", "J. Shan", "W. Zhang", "S. Su", "L. Yuwe" ],
      "venue" : "Wang, Small,",
      "citeRegEx" : "71",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "L. Cheng", "C. Wang", "L. Feng", "K. Yang", "Z. Liu" ],
      "venue" : "Rev.,",
      "citeRegEx" : "72",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Chem",
      "author" : [ "Q. Xiao", "X. Zheng", "W. Bu", "W. Ge", "S. Zhang", "F. Chen", "H. Xing", "Q. Ren", "W. Fan", "K. Zhao", "Y. Hua", "J. Shi", "J. Am" ],
      "venue" : "Soc.,",
      "citeRegEx" : "73",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Sci",
      "author" : [ "Z. Lin", "Y. Liu", "X. Ma", "S. Hu", "J. Zhang", "Q. Wu", "W. Ye", "S. Zhu", "D. Yang", "D. Qu", "J. Jiang" ],
      "venue" : "Rep.,",
      "citeRegEx" : "74",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Crit",
      "author" : [ "W. Rao", "Z.S. Deng", "J. Liu" ],
      "venue" : "Rev. Biomed. Eng.,",
      "citeRegEx" : "75",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "and P",
      "author" : [ "P. Wust", "B. Hildebrandt", "G. Sreenivasa", "B. Rau", "J. Gellermann", "H. Riess", "R. Feli" ],
      "venue" : "M. Schlag, Lancet Oncol.,",
      "citeRegEx" : "76",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "Nat",
      "author" : [ "R. Weissleder" ],
      "venue" : "Biotechnol.,",
      "citeRegEx" : "77",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "Chem",
      "author" : [ "Z. Chen", "W. Sun", "H.J. Butt", "S. Wu" ],
      "venue" : "Eur. J.,",
      "citeRegEx" : "78",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Adv",
      "author" : [ "S. Wu", "H.J. Butt" ],
      "venue" : "Mater.,",
      "citeRegEx" : "79",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Int",
      "author" : [ "I. Ahmad", "S. Ahmed", "Z. Anwar", "M.A. Sheraz", "M. Sikorski" ],
      "venue" : "J. Photoenergy,  Page 41 of 47  Journal of Materials Chemistry B Jo  ur  na  lo  fM  at  er  ia  ls  C  he  m  is  tr  y  B  A  cc  ep  te  d  M  an  us  cr  ip  t Pu  bl  is  he  d  on  0  7  Fe  br  ua  ry  2  01 7.  D  ow  nl  oa  de  d  by  U  N  IV  E  R  SI  T  Y  O  F  N  E  B  R  A  SK  A  o  n  07  /0  2/  20  17  1  3:  40  :2 3.  View Article Online DOI: 10.1039/C7TB00195A  42  2016,",
      "citeRegEx" : "80",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Adv",
      "author" : [ "P. Reineck", "A. Francis", "A. Orth", "D.W.M. Lau", "R.D.V. Nixon-Luke", "I. Das Rastogi", "W.A.W. Razali", "N.M. Cordina", "L.M. Parker", "V.K.A. Sreenivasan", "L.J. Brown", "B.C. Gibson" ],
      "venue" : "Opt. Mater.,",
      "citeRegEx" : "81",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Z",
      "author" : [ "G. Tian", "X. Zhang", "X. Zheng", "W. Yin", "L. Ruan", "X. Liu", "L. Zhou", "L. Yan", "S. Li" ],
      "venue" : "Gu and Y. Zhao, Small,",
      "citeRegEx" : "82",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and Z",
      "author" : [ "L. Cheng", "C. Yuan", "S. Shen", "X. Yi", "H. Gong", "K. Yan" ],
      "venue" : "Liu, ACS Nano,",
      "citeRegEx" : "83",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Adv",
      "author" : [ "L. Cheng", "S. Shen", "S. Shi", "Y. Yi", "X. Wang", "G. Song", "K. Yang", "G. Liu", "T.E. Barnhart", "W. Cai", "Z. Liu" ],
      "venue" : "Funct. Mater.,",
      "citeRegEx" : "84",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and C",
      "author" : [ "L. Wang", "T. Zhang", "P. Li", "W. Huang", "J. Tang", "P. Wang", "J. Liu", "Q. Yuan", "R. Bai", "B. Li", "K. Zhang", "Y. Zha" ],
      "venue" : "Chen, ACS Nano,",
      "citeRegEx" : "85",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Chem",
      "author" : [ "L. Wang", "J. Li", "J. Pan", "X. Jiang", "Y. Ji", "Y. Li", "Y. Qu", "Y. Zhao", "X. Wu", "C. Chen", "J. Am" ],
      "venue" : "Soc.,",
      "citeRegEx" : "86",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Adv",
      "author" : [ "J. Hao", "G. Song", "T. Liu", "X. Yi", "K. Yang", "L. Cheng", "Z. Liu" ],
      "venue" : "Sci.,",
      "citeRegEx" : "87",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and J",
      "author" : [ "G.R. Bhimanapati", "Z. Lin", "V. Meunier", "Y. Jung", "J. Cha", "S. Das", "D. Xiao", "Y. Son", "M.S. Strano", "V.R. Cooper", "L. Liang", "S.G. Louie", "E. Ringe", "W. Zhou", "S.S. Kim", "R.R. Naik", "B.G. Sumpter", "H. Terrones", "F. Xia", "Y. Wang", "J. Zhu", "D. Akinwande", "N. Alem", "J.A. Schuller", "R.E. Schaak", "M. Terrone" ],
      "venue" : "A. Robinson, ACS Nano,",
      "citeRegEx" : "88",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Angew",
      "author" : [ "C.N.R. Rao", "H.S.S. Matte", "U. Maitra" ],
      "venue" : "Chem. Int. Ed. Engl.,",
      "citeRegEx" : "89",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and V",
      "author" : [ "J.N. Coleman", "M. Lotya", "A. O'Neill", "S.D. Bergin", "P.J. King", "U. Khan", "K. Young", "A. Gaucher", "S. De", "R.J. Smith", "I.V. Shvets", "S.K. Arora", "G. Stanton", "H.Y. Kim", "K. Lee", "G.T. Kim", "G.S. Duesberg", "T. Hallam", "J.J. Boland", "J.J. Wang", "J.F. Donegan", "J.C. Grunlan", "G. Moriarty", "A. Shmeliov", "R.J. Nicholls", "J.M. Perkins", "E.M. Grieveson", "K. Theuwissen", "D.W. McComb", "P.D. Nellis" ],
      "venue" : "Nicolosi, Science,",
      "citeRegEx" : "90",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Annu",
      "author" : [ "C.N.R. Rao", "U. Maitra" ],
      "venue" : "Rev. Mater. Res.,",
      "citeRegEx" : "91",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and R",
      "author" : [ "A. Jawaid", "J. Che", "L.F. Drummy", "J. Bultman", "A. Waite", "M.S. Hsia" ],
      "venue" : "A. Vaia, ACS Nano,",
      "citeRegEx" : "92",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Z",
      "author" : [ "W. Yin", "L. Yan", "J. Yu", "G. Tian", "L. Zhou", "X. Zheng", "X. Zhang", "Y. Yong", "J. Li" ],
      "venue" : "Gu and  Page 42 of 47  Journal of Materials Chemistry B Jo  ur  na  lo  fM  at  er  ia  ls  C  he  m  is  tr  y  B  A  cc  ep  te  d  M  an  us  cr  ip  t Pu  bl  is  he  d  on  0  7  Fe  br  ua  ry  2  01 7.  D  ow  nl  oa  de  d  by  U  N  IV  E  R  SI  T  Y  O  F  N  E  B  R  A  SK  A  o  n  07  /0  2/  20  17  1  3:  40  :2 3.  View Article Online DOI: 10.1039/C7TB00195A  43  Y. Zhao, ACS Nano,",
      "citeRegEx" : "93",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Z",
      "author" : [ "Y. Yong", "X. Cheng", "T. Bao", "M. Zu", "L. Yan", "W. Yin", "C. Ge", "D. Wang" ],
      "venue" : "Gu and Y. Zhao, ACS Nano,",
      "citeRegEx" : "94",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Adv",
      "author" : [ "X. Chen", "A.R. McDonald" ],
      "venue" : "Mater.,",
      "citeRegEx" : "95",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Mater",
      "author" : [ "Z. Li", "S.L. Wong" ],
      "venue" : "Sci. Eng. C Mater. Biol. Appl.,",
      "citeRegEx" : "96",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Mater",
      "author" : [ "S. Presolski", "M. Pumera" ],
      "venue" : "Today,",
      "citeRegEx" : "97",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "C",
      "author" : [ "D. Voiry", "A. Goswami", "R. Kappera" ],
      "venue" : "e Silva Cde, D. Kaplan, T. Fujita, M. Chen, T. Asefa and M. Chhowalla, Nat. Chem.,",
      "citeRegEx" : "98",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Z",
      "author" : [ "L. Yan", "F. Zhao", "S. Li" ],
      "venue" : "Hu and Y. Zhao, Nanoscale,",
      "citeRegEx" : "99",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Chem",
      "author" : [ "X. Liu", "F. Fu", "K. Xu", "R. Zou", "J. Yang", "Q. Wang", "Q. Liu", "Z. Xiao", "J. Hu", "J. Mater" ],
      "venue" : "B,",
      "citeRegEx" : "100",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Adv",
      "author" : [ "T. Liu", "C. Wang", "X. Gu", "H. Gong", "L. Cheng", "X. Shi", "L. Feng", "B. Sun", "Z. Liu" ],
      "venue" : "Mater.,",
      "citeRegEx" : "101",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and Y",
      "author" : [ "L. Zou", "H. Wang", "B. He", "L. Zeng", "T. Tan", "H. Cao", "X. He", "Z. Zhang", "S. Gu" ],
      "venue" : "Li, Theranostics,",
      "citeRegEx" : "102",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Angew",
      "author" : [ "T. Sun", "Y.S. Zhang", "B. Pang", "D.C. Hyun", "M. Yang", "Y. Xia" ],
      "venue" : "Chem. Int. Ed. Engl.,",
      "citeRegEx" : "103",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "C",
      "author" : [ "C.B. Howard", "N. Fletcher", "Z.H. Houston", "A.V. Fuchs", "N.R. Boase", "J.D. Simpson", "L.J. Raftery", "T. Ruder", "M.L. Jones" ],
      "venue" : "J. de Bakker, S. M. Mahler and K. J. Thurecht, Adv. Healthc. Mater.,",
      "citeRegEx" : "104",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Nat",
      "author" : [ "J.J. Mulvey", "C.H. Villa", "M.R. McDevitt", "F.E. Escorcia", "E. Casey", "D.A. Scheinberg" ],
      "venue" : "Nanotechnol.,",
      "citeRegEx" : "105",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and Z",
      "author" : [ "T. Liu", "C. Wang", "W. Cui", "H. Gong", "C. Liang", "X. Shi", "Z. Li", "B. Su" ],
      "venue" : "Liu, Nanoscale,",
      "citeRegEx" : "106",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and Y",
      "author" : [ "Y. Yong", "L. Zhou", "Z. Gu", "L. Yan", "G. Tian", "X. Zheng", "X. Liu", "X. Zhang", "J. Shi", "W. Cong", "W. Yi" ],
      "venue" : "Zhao, Nanoscale,",
      "citeRegEx" : "107",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Chem",
      "author" : [ "X. Jia", "J. Bai", "Z. Ma", "X. Jiang", "J. Mater" ],
      "venue" : "B,",
      "citeRegEx" : "108",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Adv",
      "author" : [ "S. Wang", "Y. Chen", "X. Li", "W. Gao", "L. Zhang", "J. Liu", "Y. Zheng", "H. Chen", "J. Shi" ],
      "venue" : "Mater.,",
      "citeRegEx" : "109",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "S",
      "author" : [ "R. Deng", "H. Yi", "F. Fan", "L. Fu", "Y. Zeng", "Y. Wang", "Y. Li", "Y. Liu" ],
      "venue" : "Ji and Y. Su, RSC Adv.,",
      "citeRegEx" : "110",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and Z",
      "author" : [ "G. Yang", "H. Gong", "T. Liu", "X. Sun", "L. Chen" ],
      "venue" : "Liu, Biomaterials,",
      "citeRegEx" : "111",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Adv",
      "author" : [ "S. Wang", "X. Li", "Y. Chen", "X. Cai", "H. Yao", "W. Gao", "Y. Zheng", "X. An", "J. Shi", "H. Chen" ],
      "venue" : "Mater.,",
      "citeRegEx" : "112",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Mater",
      "author" : [ "J. Wang", "X. Tan", "X. Pang", "L. Liu", "F. Tan", "N. Li", "ACS Appl" ],
      "venue" : "Interfaces,",
      "citeRegEx" : "113",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and Z",
      "author" : [ "Y. Chao", "G. Wang", "C. Liang", "X. Yi", "X. Zhong", "J. Liu", "M. Gao", "K. Yang", "L. Chen" ],
      "venue" : "Liu, Small,",
      "citeRegEx" : "114",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and W",
      "author" : [ "J. Kim", "H. Ki" ],
      "venue" : "J. Kim, Small,",
      "citeRegEx" : "115",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Adv",
      "author" : [ "C. Zhang", "Y. Yong", "L. Song", "X. Dong", "X. Zhang", "X. Liu", "Z. Gu", "Y. Zhao", "Z. Hu" ],
      "venue" : "Healthc. Mater.,",
      "citeRegEx" : "116",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Nat",
      "author" : [ "B. Al-Lazikani", "U. Banerji", "P. Workman" ],
      "venue" : "Biotechnol.,",
      "citeRegEx" : "117",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Annu",
      "author" : [ "M.M. Gottesman" ],
      "venue" : "Rev. Med.,",
      "citeRegEx" : "118",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "J",
      "author" : [ "Q. Xue", "J. Li", "P.P. Huang", "X.R. Liu", "Z.Y. Yang", "D. Wang", "W.G. Song", "D.W. Yan", "Z.J. Gu" ],
      "venue" : "Nanosci. Nanotechnol.,",
      "citeRegEx" : "119",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Expert Opin",
      "author" : [ "M. Huo", "Y. Chen", "J. Shi" ],
      "venue" : "Drug Deliv.,",
      "citeRegEx" : "120",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Oman Med",
      "author" : [ "Z. Behrouzkia", "Z. Joveini", "B. Keshavarzi", "N. Eyvazzadeh", "R.Z. Aghdam" ],
      "venue" : "J.,",
      "citeRegEx" : "121",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Middle East Afr",
      "author" : [ "Q. Xu", "S.P. Kambhampati", "R.M. Kannan" ],
      "venue" : "J. Ophthalmol.,",
      "citeRegEx" : "122",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Methods Mol",
      "author" : [ "X.J. Liang", "C. Chen", "Y. Zhao", "P.C. Wang" ],
      "venue" : "Biol.,",
      "citeRegEx" : "123",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Int",
      "author" : [ "C.W. Song", "A. Shakil", "J.L. Osborn", "K. Iwata" ],
      "venue" : "J. Hyperthermia,",
      "citeRegEx" : "124",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Z",
      "author" : [ "T. Bao", "W. Yin", "X. Zheng", "X. Zhang", "J. Yu", "X. Dong", "Y. Yong", "F. Gao", "L. Yan" ],
      "venue" : "Gu and Y. Zhao, Biomaterials,",
      "citeRegEx" : "125",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and Z",
      "author" : [ "R. Dou", "Z. Du", "T. Bao", "X. Dong", "X. Zheng", "M. Yu", "W. Yin", "B. Dong", "L. Ya" ],
      "venue" : "Gu, Nanoscale,",
      "citeRegEx" : "126",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Adv",
      "author" : [ "Z. Zhang", "J. Wang", "C. Chen" ],
      "venue" : "Mater.,",
      "citeRegEx" : "127",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and Y",
      "author" : [ "L. Yan", "Y.N. Chang", "L. Zhao", "Z. Gu", "X. Liu", "G. Tian", "L. Zhou", "W. Ren", "S. Jin", "W.Y. Yin", "H. Chang", "G. Xing", "X. Ga" ],
      "venue" : "Zhao, Carbon,",
      "citeRegEx" : "128",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Wiley Interdiscip",
      "author" : [ "M. Arruebo" ],
      "venue" : "Rev. Nanomed. Nanobiotechnol.,",
      "citeRegEx" : "129",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "J",
      "author" : [ "H.I. Pass" ],
      "venue" : "Natl. Cancer Inst.,",
      "citeRegEx" : "130",
      "shortCiteRegEx" : null,
      "year" : 1993
    }, {
      "title" : "Adv",
      "author" : [ "X. Zhang", "G. Tian", "W. Yin", "L. Wang", "X. Zheng", "L. Yan", "J. Li", "H. Su", "C. Chen", "Z. Gu", "Y. Zhao" ],
      "venue" : "Funct. Mater.,",
      "citeRegEx" : "131",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Nat",
      "author" : [ "D.W. Felsher" ],
      "venue" : "Rev. Cancer,",
      "citeRegEx" : "132",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Chem",
      "author" : [ "S.S. Lucky", "K.C. Soo", "Y. Zhang" ],
      "venue" : "Rev.,",
      "citeRegEx" : "133",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Biomater",
      "author" : [ "L. Yan", "Y.N. Chang", "W. Yin", "G. Tian", "L. Zhou", "X. Liu", "G. Xing", "L. Zhao", "Z. Gu", "Y. Zhao" ],
      "venue" : "Sci.,",
      "citeRegEx" : "134",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Int",
      "author" : [ "C.W. Song", "H.J. Park", "C.K. Lee", "R. Griffin" ],
      "venue" : "J. Hyperthermia,",
      "citeRegEx" : "135",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Adv",
      "author" : [ "D.K. Ji", "Y. Zhang", "Y. Zang", "J. Li", "G.R. Chen", "X.P. He", "H. Tian" ],
      "venue" : "Mater.,",
      "citeRegEx" : "136",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Mater",
      "author" : [ "H. Dong", "S. Tang", "Y. Hao", "H. Yu", "W. Dai", "G. Zhao", "Y. Cao", "H. Lu", "X. Zhang", "H. Ju", "ACS Appl" ],
      "venue" : "Interfaces,",
      "citeRegEx" : "137",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and Z",
      "author" : [ "B. Tian", "C. Wang", "S. Zhang", "L. Fen" ],
      "venue" : "Liu, ACS Nano,",
      "citeRegEx" : "138",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and G",
      "author" : [ "H. Wang", "Z.C. Zeng", "T.A. Bui", "S.J. DiBiase", "W. Qin", "F. Xia", "S.N. Powel" ],
      "venue" : "Iliakis, Cancer Res.,",
      "citeRegEx" : "139",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "Clin",
      "author" : [ "T.W. Meijer", "J.H. Kaanders", "P.N. Span", "J. Bussink" ],
      "venue" : "Cancer Res.,",
      "citeRegEx" : "140",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and W",
      "author" : [ "J. Qiu", "Q. Xiao", "X. Zheng", "L. Zhang", "H. Xing", "D. Ni", "Y. Liu", "S. Zhang", "Q. Ren", "Y. Hua", "K. Zha" ],
      "venue" : "Bu, Nano Res.,",
      "citeRegEx" : "141",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Clin",
      "author" : [ "M.R. Horsman", "J. Overgaard" ],
      "venue" : "Oncol.,",
      "citeRegEx" : "142",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Radiat",
      "author" : [ "L.E. Gerweck", "E.L. Gillette", "W.C. Dewey" ],
      "venue" : "Res.,",
      "citeRegEx" : "143",
      "shortCiteRegEx" : null,
      "year" : 1975
    }, {
      "title" : "and P",
      "author" : [ "J. Overgaar" ],
      "venue" : "Bichel, Radiology,",
      "citeRegEx" : "144",
      "shortCiteRegEx" : null,
      "year" : 1977
    }, {
      "title" : "in Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer, eds",
      "author" : [ "T. Paunesku", "S. Gutiontov", "K. Brown", "G.E. Woloschak" ],
      "venue" : "C. A. Mirkin, T. J. Meade, S. H. Petrosko and A. H. Stegh, Springer International Publishing, Cham,",
      "citeRegEx" : "145",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and D",
      "author" : [ "A. Bettaieb", "P.K. Wrza" ],
      "venue" : "A. Averill-Bates, in Cancer Treatment - Conventional and Innovative Approaches, InTech, Rijeka,",
      "citeRegEx" : "146",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Clin",
      "author" : [ "D. Cross", "J.K. Burmester" ],
      "venue" : "Med. Res.,",
      "citeRegEx" : "147",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Adv",
      "author" : [ "G. Ozcan", "B. Ozpolat", "R.L. Coleman", "A.K. Sood", "G. Lopez-Berestein" ],
      "venue" : "Drug Deliv. Rev.,",
      "citeRegEx" : "148",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "B",
      "author" : [ "M.K. Jayakumar", "A. Bansal", "K. Huang", "R. Yao" ],
      "venue" : "N. Li and Y. Zhang, ACS Nano,",
      "citeRegEx" : "149",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "45 of 47  Journal of Materials Chemistry B Jo  ur  na  lo  fM  at  er  ia  ls  C  he  m  is  tr  y  B  A  cc  ep  te  d  M  an  us  cr  ip  t Pu  bl  is  he  d  on  0  7  Fe  br  ua  ry  2  01 7",
      "author" : [ "Z. Kou", "X. Wang", "R. Yuan", "H. Chen", "Q. Zhi", "L. Gao", "B. Wang", "Z. Guo", "X. Xue", "W.  Pag" ],
      "venue" : " D  ow  nl  oa  de  d  by  U  N  IV  E  R  SI  T  Y  O  F  N  E  B  R  A  SK  A  o  n  07  /0  2/  20  17  1  3:  40  :2 3.  View Article Online DOI: 10.1039/C7TB00195A  46 Cao and L. Guo, Nanoscale Res. Lett.,",
      "citeRegEx" : "150",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Adv",
      "author" : [ "J. Kim", "J. Kim", "C. Jeong", "W.J. Kim" ],
      "venue" : "Drug Deliv. Rev.,",
      "citeRegEx" : "151",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Nat",
      "author" : [ "H. Yin", "R.L. Kanasty", "A.A. Eltoukhy", "A.J. Vegas", "J.R. Dorkin", "D.G. Anderson" ],
      "venue" : "Rev. Genet.,",
      "citeRegEx" : "152",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Biomater",
      "author" : [ "E. Keles", "Y. Song", "D. Du", "W.J. Dong", "Y. Lin" ],
      "venue" : "Sci.,",
      "citeRegEx" : "153",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and A",
      "author" : [ "P. Kaur", "M.D. Hurwitz", "S. Krishna" ],
      "venue" : "Asea, Cancers,",
      "citeRegEx" : "154",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Z",
      "author" : [ "X. Zheng", "J. Shi", "Y. Bu", "G. Tian", "X. Zhang", "W. Yin", "B. Gao", "Z. Yang", "Z. Hu", "X. Liu", "L. Yan" ],
      "venue" : "Gu and Y. Zhao, Nanoscale,",
      "citeRegEx" : "155",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Biomed",
      "author" : [ "J. Xia", "L.V. Wang", "IEEE Trans" ],
      "venue" : "Eng.,",
      "citeRegEx" : "156",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Nat",
      "author" : [ "J. Weber", "P.C. Beard", "S.E. Bohndiek" ],
      "venue" : "Meth.,",
      "citeRegEx" : "157",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and S",
      "author" : [ "L.V. Wan" ],
      "venue" : "Hu, Science,",
      "citeRegEx" : "158",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "and C",
      "author" : [ "J. Kim", "D. Lee", "U. Jun" ],
      "venue" : "Kim, Ultrasonography,",
      "citeRegEx" : "159",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Nat",
      "author" : [ "M. Lakshman", "A. Needles" ],
      "venue" : "Meth.,",
      "citeRegEx" : "160",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Adv",
      "author" : [ "J. Chen", "C. Liu", "D. Hu", "F. Wang", "H. Wu", "X. Gong", "X. Liu", "L. Song", "Z. Sheng", "H. Zheng" ],
      "venue" : "Funct. Mater.,",
      "citeRegEx" : "161",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "and Z",
      "author" : [ "X. Qian", "S. Shen", "T. Liu", "L. Chen" ],
      "venue" : "Liu, Nanoscale,",
      "citeRegEx" : "162",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and P",
      "author" : [ "H. Xie", "Z. Li", "Z. Sun", "J. Shao", "X.F. Yu", "Z. Guo", "J. Wang", "Q. Xiao", "H. Wang", "Q.Q. Wang", "H. Zhan" ],
      "venue" : "K. Chu, Small,",
      "citeRegEx" : "163",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Mater",
      "author" : [ "R. Anbazhagan", "Y.A. Su", "H.C. Tsai", "R.J. Jeng", "ACS Appl" ],
      "venue" : "Interfaces,",
      "citeRegEx" : "164",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Adv",
      "author" : [ "X.-D. Zhang", "J. Chen", "Y. Min", "G.B. Park", "X. Shen", "S.-S. Song", "Y.-M. Sun", "H. Wang", "W. Long", "J. Xie", "K. Gao", "L. Zhang", "S. Fan", "F. Fan", "U. Jeong" ],
      "venue" : "Funct. Mater.,",
      "citeRegEx" : "165",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Nat",
      "author" : [ "O. Rabin", "J. Manuel Perez", "J. Grimm", "G. Wojtkiewicz", "R. Weissleder" ],
      "venue" : "Mater.,",
      "citeRegEx" : "166",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Sci",
      "author" : [ "J. Li", "F. Jiang", "B. Yang", "X.R. Song", "Y. Liu", "H.H. Yang", "D.R. Cao", "W.R. Shi", "G.N. Chen" ],
      "venue" : "Rep., 2013, 3,",
      "citeRegEx" : "167",
      "shortCiteRegEx" : null,
      "year" : 1998
    }, {
      "title" : "Chin",
      "author" : [ "X.Z. Cui", "Z.G. Zhou", "Y. Yang", "J. Wei", "J. Wang", "M.W. Wang", "H. Yang", "Y.J. Zhang", "S.P. Yang" ],
      "venue" : "Chem. Lett.,",
      "citeRegEx" : "168",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "N",
      "author" : [ "J.K. Willmann" ],
      "venue" : "van Bruggen, L. M. Dinkelborg and S. S. Gambhir, Nat. Rev. Drug Discov.,",
      "citeRegEx" : "169",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "X",
      "author" : [ "J. Yu", "W. Yin", "X. Zheng", "G. Tian", "X. Zhang", "T. Bao", "X. Dong", "Z. Wang", "Z. Gu" ],
      "venue" : "Ma and Y. Zhao, Theranostics,",
      "citeRegEx" : "170",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Adv",
      "author" : [ "L. Cheng", "J. Liu", "X. Gu", "H. Gong", "X. Shi", "T. Liu", "C. Wang", "X. Wang", "G. Liu", "H. Xing", "W. Bu", "B. Sun", "Z. Liu" ],
      "venue" : "Mater.,",
      "citeRegEx" : "171",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and Z",
      "author" : [ "T. Liu", "S. Shi", "C. Liang", "S. Shen", "L. Cheng", "C. Wang", "X. Song", "S. Goel", "T.E. Barnhart", "W. Ca" ],
      "venue" : "Liu, ACS Nano,",
      "citeRegEx" : "172",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "ChemNanoMat, 2016, DOI: 10.1002/cnma.201600290",
      "author" : [ "Kenry", "C.T. Lim" ],
      "venue" : null,
      "citeRegEx" : "173",
      "shortCiteRegEx" : "173",
      "year" : 2016
    }, {
      "title" : "and M",
      "author" : [ "E.L. Chng", "Z. Sofe" ],
      "venue" : "Pumera, Nanoscale,",
      "citeRegEx" : "174",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "and J",
      "author" : [ "S. Wang", "K. Li", "Y. Chen", "H. Chen", "M. Ma", "J. Feng", "Q. Zha" ],
      "venue" : "Shi, Biomaterials,",
      "citeRegEx" : "175",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and M",
      "author" : [ "E.L. Chn" ],
      "venue" : "Pumera, RSC Adv.,",
      "citeRegEx" : "176",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Chem",
      "author" : [ "N.M. Latiff", "Z. Sofer", "A.C. Fisher", "M. Pumera" ],
      "venue" : "Eur. J.,",
      "citeRegEx" : "177",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Proc",
      "author" : [ "J.R. Heath" ],
      "venue" : "Natl. Acad. Sci. U. S. A.,",
      "citeRegEx" : "178",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "and A",
      "author" : [ "H.L. Jang", "Y.S. Zhan" ],
      "venue" : "Khademhosseini, Nanomedicne,",
      "citeRegEx" : "179",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Nat",
      "author" : [ "K. Kostarelos" ],
      "venue" : "Rev. Mater.,",
      "citeRegEx" : "180",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "Y. Min", "J.M. Caster", "M.J. Eblan", "A.Z. Wang" ],
      "venue" : "Rev.,",
      "citeRegEx" : "181",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Nat",
      "author" : [ "W.R. Sanhai", "J.H. Sakamoto", "R. Canady", "M. Ferrari" ],
      "venue" : "Nanotechnol.,",
      "citeRegEx" : "182",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Chem",
      "author" : [ "S. Sharifi", "S. Behzadi", "S. Laurent", "M.L. Forrest", "P. Stroeve", "M. Mahmoudi" ],
      "venue" : "Soc. Rev.,",
      "citeRegEx" : "184",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Curr",
      "author" : [ "H.C. Fischer", "W.C. Chan" ],
      "venue" : "Opin. Biotechnol.,",
      "citeRegEx" : "185",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Nat",
      "author" : [ "M.A. Dobrovolskaia", "D.R. Germolec", "J.L. Weaver" ],
      "venue" : "Nanotechnol.,",
      "citeRegEx" : "186",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Toxicol",
      "author" : [ "M.J. Smith", "J.M. Brown", "W.C. Zamboni", "N.J. Walker" ],
      "venue" : "Sci.,",
      "citeRegEx" : "187",
      "shortCiteRegEx" : null,
      "year" : 2014
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "With the rapid development of nanoscience, nanomaterial-assisted combination therapies have arguably become the most active area in medicine research, which represents the arrival of a new era of “cancer nanomedicine”.(1-11) Among these treatment strategies, photothermal combination therapy, which refers to the simultaneous or continuous administration of nanomaterial-based photothermal therapy (PTT) with other therapeutic techniques, such as chemotherapy, shows a significant promise comparing to mono PTT because of its advantages in improving therapeutic efficacy, reducing side-effects and overcoming multi-drug resistance (MDR) (Fig.",
      "startOffset" : 217,
      "endOffset" : 224
    }, {
      "referenceID" : 1,
      "context" : "With the rapid development of nanoscience, nanomaterial-assisted combination therapies have arguably become the most active area in medicine research, which represents the arrival of a new era of “cancer nanomedicine”.(1-11) Among these treatment strategies, photothermal combination therapy, which refers to the simultaneous or continuous administration of nanomaterial-based photothermal therapy (PTT) with other therapeutic techniques, such as chemotherapy, shows a significant promise comparing to mono PTT because of its advantages in improving therapeutic efficacy, reducing side-effects and overcoming multi-drug resistance (MDR) (Fig.",
      "startOffset" : 217,
      "endOffset" : 224
    }, {
      "referenceID" : 2,
      "context" : "With the rapid development of nanoscience, nanomaterial-assisted combination therapies have arguably become the most active area in medicine research, which represents the arrival of a new era of “cancer nanomedicine”.(1-11) Among these treatment strategies, photothermal combination therapy, which refers to the simultaneous or continuous administration of nanomaterial-based photothermal therapy (PTT) with other therapeutic techniques, such as chemotherapy, shows a significant promise comparing to mono PTT because of its advantages in improving therapeutic efficacy, reducing side-effects and overcoming multi-drug resistance (MDR) (Fig.",
      "startOffset" : 217,
      "endOffset" : 224
    }, {
      "referenceID" : 3,
      "context" : "With the rapid development of nanoscience, nanomaterial-assisted combination therapies have arguably become the most active area in medicine research, which represents the arrival of a new era of “cancer nanomedicine”.(1-11) Among these treatment strategies, photothermal combination therapy, which refers to the simultaneous or continuous administration of nanomaterial-based photothermal therapy (PTT) with other therapeutic techniques, such as chemotherapy, shows a significant promise comparing to mono PTT because of its advantages in improving therapeutic efficacy, reducing side-effects and overcoming multi-drug resistance (MDR) (Fig.",
      "startOffset" : 217,
      "endOffset" : 224
    }, {
      "referenceID" : 4,
      "context" : "With the rapid development of nanoscience, nanomaterial-assisted combination therapies have arguably become the most active area in medicine research, which represents the arrival of a new era of “cancer nanomedicine”.(1-11) Among these treatment strategies, photothermal combination therapy, which refers to the simultaneous or continuous administration of nanomaterial-based photothermal therapy (PTT) with other therapeutic techniques, such as chemotherapy, shows a significant promise comparing to mono PTT because of its advantages in improving therapeutic efficacy, reducing side-effects and overcoming multi-drug resistance (MDR) (Fig.",
      "startOffset" : 217,
      "endOffset" : 224
    }, {
      "referenceID" : 5,
      "context" : "With the rapid development of nanoscience, nanomaterial-assisted combination therapies have arguably become the most active area in medicine research, which represents the arrival of a new era of “cancer nanomedicine”.(1-11) Among these treatment strategies, photothermal combination therapy, which refers to the simultaneous or continuous administration of nanomaterial-based photothermal therapy (PTT) with other therapeutic techniques, such as chemotherapy, shows a significant promise comparing to mono PTT because of its advantages in improving therapeutic efficacy, reducing side-effects and overcoming multi-drug resistance (MDR) (Fig.",
      "startOffset" : 217,
      "endOffset" : 224
    }, {
      "referenceID" : 6,
      "context" : "With the rapid development of nanoscience, nanomaterial-assisted combination therapies have arguably become the most active area in medicine research, which represents the arrival of a new era of “cancer nanomedicine”.(1-11) Among these treatment strategies, photothermal combination therapy, which refers to the simultaneous or continuous administration of nanomaterial-based photothermal therapy (PTT) with other therapeutic techniques, such as chemotherapy, shows a significant promise comparing to mono PTT because of its advantages in improving therapeutic efficacy, reducing side-effects and overcoming multi-drug resistance (MDR) (Fig.",
      "startOffset" : 217,
      "endOffset" : 224
    }, {
      "referenceID" : 7,
      "context" : "With the rapid development of nanoscience, nanomaterial-assisted combination therapies have arguably become the most active area in medicine research, which represents the arrival of a new era of “cancer nanomedicine”.(1-11) Among these treatment strategies, photothermal combination therapy, which refers to the simultaneous or continuous administration of nanomaterial-based photothermal therapy (PTT) with other therapeutic techniques, such as chemotherapy, shows a significant promise comparing to mono PTT because of its advantages in improving therapeutic efficacy, reducing side-effects and overcoming multi-drug resistance (MDR) (Fig.",
      "startOffset" : 217,
      "endOffset" : 224
    }, {
      "referenceID" : 8,
      "context" : "With the rapid development of nanoscience, nanomaterial-assisted combination therapies have arguably become the most active area in medicine research, which represents the arrival of a new era of “cancer nanomedicine”.(1-11) Among these treatment strategies, photothermal combination therapy, which refers to the simultaneous or continuous administration of nanomaterial-based photothermal therapy (PTT) with other therapeutic techniques, such as chemotherapy, shows a significant promise comparing to mono PTT because of its advantages in improving therapeutic efficacy, reducing side-effects and overcoming multi-drug resistance (MDR) (Fig.",
      "startOffset" : 217,
      "endOffset" : 224
    }, {
      "referenceID" : 9,
      "context" : "With the rapid development of nanoscience, nanomaterial-assisted combination therapies have arguably become the most active area in medicine research, which represents the arrival of a new era of “cancer nanomedicine”.(1-11) Among these treatment strategies, photothermal combination therapy, which refers to the simultaneous or continuous administration of nanomaterial-based photothermal therapy (PTT) with other therapeutic techniques, such as chemotherapy, shows a significant promise comparing to mono PTT because of its advantages in improving therapeutic efficacy, reducing side-effects and overcoming multi-drug resistance (MDR) (Fig.",
      "startOffset" : 217,
      "endOffset" : 224
    }, {
      "referenceID" : 10,
      "context" : "With the rapid development of nanoscience, nanomaterial-assisted combination therapies have arguably become the most active area in medicine research, which represents the arrival of a new era of “cancer nanomedicine”.(1-11) Among these treatment strategies, photothermal combination therapy, which refers to the simultaneous or continuous administration of nanomaterial-based photothermal therapy (PTT) with other therapeutic techniques, such as chemotherapy, shows a significant promise comparing to mono PTT because of its advantages in improving therapeutic efficacy, reducing side-effects and overcoming multi-drug resistance (MDR) (Fig.",
      "startOffset" : 217,
      "endOffset" : 224
    }, {
      "referenceID" : 11,
      "context" : "1).(12-15) Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.",
      "startOffset" : 2,
      "endOffset" : 10
    }, {
      "referenceID" : 12,
      "context" : "1).(12-15) Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.",
      "startOffset" : 2,
      "endOffset" : 10
    }, {
      "referenceID" : 13,
      "context" : "1).(12-15) Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.",
      "startOffset" : 2,
      "endOffset" : 10
    }, {
      "referenceID" : 14,
      "context" : "1).(12-15) Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.",
      "startOffset" : 2,
      "endOffset" : 10
    }, {
      "referenceID" : 15,
      "context" : "Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.(16-26) For example, Zhang et al.",
      "startOffset" : 341,
      "endOffset" : 349
    }, {
      "referenceID" : 16,
      "context" : "Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.(16-26) For example, Zhang et al.",
      "startOffset" : 341,
      "endOffset" : 349
    }, {
      "referenceID" : 17,
      "context" : "Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.(16-26) For example, Zhang et al.",
      "startOffset" : 341,
      "endOffset" : 349
    }, {
      "referenceID" : 18,
      "context" : "Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.(16-26) For example, Zhang et al.",
      "startOffset" : 341,
      "endOffset" : 349
    }, {
      "referenceID" : 19,
      "context" : "Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.(16-26) For example, Zhang et al.",
      "startOffset" : 341,
      "endOffset" : 349
    }, {
      "referenceID" : 20,
      "context" : "Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.(16-26) For example, Zhang et al.",
      "startOffset" : 341,
      "endOffset" : 349
    }, {
      "referenceID" : 21,
      "context" : "Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.(16-26) For example, Zhang et al.",
      "startOffset" : 341,
      "endOffset" : 349
    }, {
      "referenceID" : 22,
      "context" : "Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.(16-26) For example, Zhang et al.",
      "startOffset" : 341,
      "endOffset" : 349
    }, {
      "referenceID" : 23,
      "context" : "Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.(16-26) For example, Zhang et al.",
      "startOffset" : 341,
      "endOffset" : 349
    }, {
      "referenceID" : 24,
      "context" : "Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.(16-26) For example, Zhang et al.",
      "startOffset" : 341,
      "endOffset" : 349
    }, {
      "referenceID" : 25,
      "context" : "Recently, owing to the effective absorption property in the near-infrared (NIR) region as well as extremely large specific surface area, graphene and its derivatives, as the typical ultrathin two-dimensional (2D) layer nanomaterials, have gained tremendous attention as the multifunctional nanoplatform to combine PTT with other therapeutics.(16-26) For example, Zhang et al.",
      "startOffset" : 341,
      "endOffset" : 349
    }, {
      "referenceID" : 26,
      "context" : "utilized PEGylated graphene oxide as a nanocarrier to load anticancer drug and where they demonstrated that the mice treated with the obtained nanocomplex showed more excellent therapeutic effect compared to those treated by drug or the nanocomposite with laser irradiation alone.(27) More recently, driven by the success of graphene for biomedicine, the rapid progress of research has stimulated a lot of interest in other layered 2D nanomaterials.",
      "startOffset" : 280,
      "endOffset" : 284
    }, {
      "referenceID" : 27,
      "context" : "More recently, driven by the success of graphene for biomedicine, the rapid progress of research has stimulated a lot of interest in other layered 2D nanomaterials.(28-30) Previous studies on several representative 2D nanomaterials, such as black phosphorus (BP) nanosheets,(31) boron nitride (BN),(32-34) and graphitic carbon nitride (g-C3N4), 35-37 have successfully proved that 2D nanomaterials possess not only high photothermal conversion efficiency but also large surface area which are highly favorable to deliver biomolecules and drugs into cells for cancer treatment.",
      "startOffset" : 163,
      "endOffset" : 171
    }, {
      "referenceID" : 28,
      "context" : "More recently, driven by the success of graphene for biomedicine, the rapid progress of research has stimulated a lot of interest in other layered 2D nanomaterials.(28-30) Previous studies on several representative 2D nanomaterials, such as black phosphorus (BP) nanosheets,(31) boron nitride (BN),(32-34) and graphitic carbon nitride (g-C3N4), 35-37 have successfully proved that 2D nanomaterials possess not only high photothermal conversion efficiency but also large surface area which are highly favorable to deliver biomolecules and drugs into cells for cancer treatment.",
      "startOffset" : 163,
      "endOffset" : 171
    }, {
      "referenceID" : 29,
      "context" : "More recently, driven by the success of graphene for biomedicine, the rapid progress of research has stimulated a lot of interest in other layered 2D nanomaterials.(28-30) Previous studies on several representative 2D nanomaterials, such as black phosphorus (BP) nanosheets,(31) boron nitride (BN),(32-34) and graphitic carbon nitride (g-C3N4), 35-37 have successfully proved that 2D nanomaterials possess not only high photothermal conversion efficiency but also large surface area which are highly favorable to deliver biomolecules and drugs into cells for cancer treatment.",
      "startOffset" : 163,
      "endOffset" : 171
    }, {
      "referenceID" : 37,
      "context" : "In the rich family of 2D nanomaterials, 2D transition metal dichalcogenides (TMDCs) have becoming the focus of fundamental research and technological applications.(38-42) Analogous to graphene, as shown in Fig.",
      "startOffset" : 162,
      "endOffset" : 170
    }, {
      "referenceID" : 38,
      "context" : "In the rich family of 2D nanomaterials, 2D transition metal dichalcogenides (TMDCs) have becoming the focus of fundamental research and technological applications.(38-42) Analogous to graphene, as shown in Fig.",
      "startOffset" : 162,
      "endOffset" : 170
    }, {
      "referenceID" : 39,
      "context" : "In the rich family of 2D nanomaterials, 2D transition metal dichalcogenides (TMDCs) have becoming the focus of fundamental research and technological applications.(38-42) Analogous to graphene, as shown in Fig.",
      "startOffset" : 162,
      "endOffset" : 170
    }, {
      "referenceID" : 40,
      "context" : "In the rich family of 2D nanomaterials, 2D transition metal dichalcogenides (TMDCs) have becoming the focus of fundamental research and technological applications.(38-42) Analogous to graphene, as shown in Fig.",
      "startOffset" : 162,
      "endOffset" : 170
    }, {
      "referenceID" : 41,
      "context" : "In the rich family of 2D nanomaterials, 2D transition metal dichalcogenides (TMDCs) have becoming the focus of fundamental research and technological applications.(38-42) Analogous to graphene, as shown in Fig.",
      "startOffset" : 162,
      "endOffset" : 170
    }, {
      "referenceID" : 42,
      "context" : "2, 2D TMDCs consists a hexagonal layer of transition metal atoms (M) sandwiched between two layers of chalcogen atoms (X) with a MX2 stoichiometry, where M ranges from Group IVB to Group VIII (such as Ti, V, Nb, Mo, Hf, Ta, and W), and X stands for the chalcogen (S, Se, and Te).(43-45) Together with topological insulators (such as Bi2Se3), more than 40 types of 2D TMDCs can occur depending on the combination of M and X as well as their diverse arrangements.",
      "startOffset" : 278,
      "endOffset" : 286
    }, {
      "referenceID" : 43,
      "context" : "2, 2D TMDCs consists a hexagonal layer of transition metal atoms (M) sandwiched between two layers of chalcogen atoms (X) with a MX2 stoichiometry, where M ranges from Group IVB to Group VIII (such as Ti, V, Nb, Mo, Hf, Ta, and W), and X stands for the chalcogen (S, Se, and Te).(43-45) Together with topological insulators (such as Bi2Se3), more than 40 types of 2D TMDCs can occur depending on the combination of M and X as well as their diverse arrangements.",
      "startOffset" : 278,
      "endOffset" : 286
    }, {
      "referenceID" : 44,
      "context" : "2, 2D TMDCs consists a hexagonal layer of transition metal atoms (M) sandwiched between two layers of chalcogen atoms (X) with a MX2 stoichiometry, where M ranges from Group IVB to Group VIII (such as Ti, V, Nb, Mo, Hf, Ta, and W), and X stands for the chalcogen (S, Se, and Te).(43-45) Together with topological insulators (such as Bi2Se3), more than 40 types of 2D TMDCs can occur depending on the combination of M and X as well as their diverse arrangements.",
      "startOffset" : 278,
      "endOffset" : 286
    }, {
      "referenceID" : 42,
      "context" : "Together with topological insulators (such as Bi2Se3), more than 40 types of 2D TMDCs can occur depending on the combination of M and X as well as their diverse arrangements.(43) This special structure and various combinations of atoms endow 2D TMDCs with a substantial range of properties (Fig.",
      "startOffset" : 174,
      "endOffset" : 178
    }, {
      "referenceID" : 48,
      "context" : "2), such as unique electronic and optical properties, 44, 45 tunable energy band, large surface areas and low cytotoxicity,(46-48) all of which make them suitable for applications in a large variety of fields including electronics, optics, nanocomposites, energy research and catalysis.(49-57) Page 4 of 47 Journal of Materials Chemistry B",
      "startOffset" : 285,
      "endOffset" : 293
    }, {
      "referenceID" : 49,
      "context" : "2), such as unique electronic and optical properties, 44, 45 tunable energy band, large surface areas and low cytotoxicity,(46-48) all of which make them suitable for applications in a large variety of fields including electronics, optics, nanocomposites, energy research and catalysis.(49-57) Page 4 of 47 Journal of Materials Chemistry B",
      "startOffset" : 285,
      "endOffset" : 293
    }, {
      "referenceID" : 50,
      "context" : "2), such as unique electronic and optical properties, 44, 45 tunable energy band, large surface areas and low cytotoxicity,(46-48) all of which make them suitable for applications in a large variety of fields including electronics, optics, nanocomposites, energy research and catalysis.(49-57) Page 4 of 47 Journal of Materials Chemistry B",
      "startOffset" : 285,
      "endOffset" : 293
    }, {
      "referenceID" : 51,
      "context" : "2), such as unique electronic and optical properties, 44, 45 tunable energy band, large surface areas and low cytotoxicity,(46-48) all of which make them suitable for applications in a large variety of fields including electronics, optics, nanocomposites, energy research and catalysis.(49-57) Page 4 of 47 Journal of Materials Chemistry B",
      "startOffset" : 285,
      "endOffset" : 293
    }, {
      "referenceID" : 52,
      "context" : "2), such as unique electronic and optical properties, 44, 45 tunable energy band, large surface areas and low cytotoxicity,(46-48) all of which make them suitable for applications in a large variety of fields including electronics, optics, nanocomposites, energy research and catalysis.(49-57) Page 4 of 47 Journal of Materials Chemistry B",
      "startOffset" : 285,
      "endOffset" : 293
    }, {
      "referenceID" : 53,
      "context" : "2), such as unique electronic and optical properties, 44, 45 tunable energy band, large surface areas and low cytotoxicity,(46-48) all of which make them suitable for applications in a large variety of fields including electronics, optics, nanocomposites, energy research and catalysis.(49-57) Page 4 of 47 Journal of Materials Chemistry B",
      "startOffset" : 285,
      "endOffset" : 293
    }, {
      "referenceID" : 54,
      "context" : "2), such as unique electronic and optical properties, 44, 45 tunable energy band, large surface areas and low cytotoxicity,(46-48) all of which make them suitable for applications in a large variety of fields including electronics, optics, nanocomposites, energy research and catalysis.(49-57) Page 4 of 47 Journal of Materials Chemistry B",
      "startOffset" : 285,
      "endOffset" : 293
    }, {
      "referenceID" : 55,
      "context" : "2), such as unique electronic and optical properties, 44, 45 tunable energy band, large surface areas and low cytotoxicity,(46-48) all of which make them suitable for applications in a large variety of fields including electronics, optics, nanocomposites, energy research and catalysis.(49-57) Page 4 of 47 Journal of Materials Chemistry B",
      "startOffset" : 285,
      "endOffset" : 293
    }, {
      "referenceID" : 56,
      "context" : "2), such as unique electronic and optical properties, 44, 45 tunable energy band, large surface areas and low cytotoxicity,(46-48) all of which make them suitable for applications in a large variety of fields including electronics, optics, nanocomposites, energy research and catalysis.(49-57) Page 4 of 47 Journal of Materials Chemistry B",
      "startOffset" : 285,
      "endOffset" : 293
    }, {
      "referenceID" : 61,
      "context" : "anticancer drugs for applications in biosensors, drug delivery, gene transfection and tissue engineering.(63-65) By utilizing their intrinsic high NIR absorbance as well as low toxicity, 2D",
      "startOffset" : 104,
      "endOffset" : 112
    }, {
      "referenceID" : 62,
      "context" : "anticancer drugs for applications in biosensors, drug delivery, gene transfection and tissue engineering.(63-65) By utilizing their intrinsic high NIR absorbance as well as low toxicity, 2D",
      "startOffset" : 104,
      "endOffset" : 112
    }, {
      "referenceID" : 63,
      "context" : "anticancer drugs for applications in biosensors, drug delivery, gene transfection and tissue engineering.(63-65) By utilizing their intrinsic high NIR absorbance as well as low toxicity, 2D",
      "startOffset" : 104,
      "endOffset" : 112
    }, {
      "referenceID" : 64,
      "context" : "TMDCs have also been used as photothermal agents for PTT of cancer with encouraging therapeutic outcomes.(66-68) Therefore, thanks to their excellent photothermal effects, large surface area, and versatile surface chemistries, 2D TMDCs have great potential as a platform to integrate PTT with other therapeutic moieties, which endows them with highly enriched",
      "startOffset" : 104,
      "endOffset" : 112
    }, {
      "referenceID" : 65,
      "context" : "TMDCs have also been used as photothermal agents for PTT of cancer with encouraging therapeutic outcomes.(66-68) Therefore, thanks to their excellent photothermal effects, large surface area, and versatile surface chemistries, 2D TMDCs have great potential as a platform to integrate PTT with other therapeutic moieties, which endows them with highly enriched",
      "startOffset" : 104,
      "endOffset" : 112
    }, {
      "referenceID" : 66,
      "context" : "TMDCs have also been used as photothermal agents for PTT of cancer with encouraging therapeutic outcomes.(66-68) Therefore, thanks to their excellent photothermal effects, large surface area, and versatile surface chemistries, 2D TMDCs have great potential as a platform to integrate PTT with other therapeutic moieties, which endows them with highly enriched",
      "startOffset" : 104,
      "endOffset" : 112
    }, {
      "referenceID" : 72,
      "context" : "73 However, many preclinical and clinical studies have shown that PTT alone is often difficult to completely eradicate tumors due to the inhomogeneous heat distribution within tumor tissues and the failure of killing the deep-located tumors because of the inevitable depth-dependent decline of laser intensity, which are the intrinsic drawbacks of optical therapy.(74) In addition, hyperthermia not only eradicate the cancer cells but also cause damage to healthy tissue, leading to potential side-effect.",
      "startOffset" : 364,
      "endOffset" : 368
    }, {
      "referenceID" : 73,
      "context" : "side-effects through multiple mechanisms such as sensitization and motivating anti-tumor immune function, and finally enhance the anti-cancer efficacy as well as avoid high-dose-induced toxicity toward normal tissue.(75) Thus, photothermal combination therapy is of hope for the fabrication of the next generation of anticancer tools.",
      "startOffset" : 216,
      "endOffset" : 220
    }, {
      "referenceID" : 75,
      "context" : "From this point of view, 2D TMDCs are ideal photothermal agents to convert NIR light into heat to kill cancer cells.(77) 2) High photothermal conversion efficiency.",
      "startOffset" : 116,
      "endOffset" : 120
    }, {
      "referenceID" : 64,
      "context" : "As expected, most 2D TMDCs exhibit a strong absorption in NIR region and display high photothermal conversion efficiency which is comparable to that of other nanoscale photothermal agents such as gold nanoparticles.(66) 3) High photostability.",
      "startOffset" : 215,
      "endOffset" : 219
    }, {
      "referenceID" : 80,
      "context" : "This feature helps to realize the on-demand drug release at the desired site and time with controllable therapeutic outcome owing to the high spatial-temporal resolution of NIR light stimuli.(82) On the other hand, a few 2D TMDCs that contain high Z elements such as WS2 and Bi2Se3 have strong X-ray attenuation ability, which makes them possible to be used as efficient radio-sensitizers for RT of cancer.",
      "startOffset" : 191,
      "endOffset" : 195
    }, {
      "referenceID" : 39,
      "context" : "88-90 Liquid-phase exfoliation method has been shown to yield the single-layer 2D TMDCs with good biocompatibility.(40) A basic liquid-phase",
      "startOffset" : 115,
      "endOffset" : 119
    }, {
      "referenceID" : 64,
      "context" : "90-92 Both Chou et al.(66) and Yin et al.",
      "startOffset" : 22,
      "endOffset" : 26
    }, {
      "referenceID" : 91,
      "context" : "and Yin et al.(93) reported a simple approach based on ultrasonication of intercalated MoS2 powder.",
      "startOffset" : 14,
      "endOffset" : 18
    }, {
      "referenceID" : 92,
      "context" : "To increase the yield of 2D TMDCs with small size, Yong et al.(94) used ball milling method to cut the layered materials down to nanoscale sizes and then the nanoscale layered materials exfoliated by ultrasonication.",
      "startOffset" : 62,
      "endOffset" : 66
    }, {
      "referenceID" : 61,
      "context" : "For example, poly(acrylic acid) (PAA) and polyethylene glycol (PEG) could be coated onto the surface of WS2 via the relatively strong coordination interaction between carboxyl groups and tungsten atoms, aiming to improve their stability in water and physiological solutions.(63) Alternatively, targeting moieties, such as folic acid (FA), 101 peptides, 103 and antibodies,(103-105) may also be integrated with 2D TMDCs to enhance their targeting ability, so that they could be selectively taken up by cancer cells and then",
      "startOffset" : 274,
      "endOffset" : 278
    }, {
      "referenceID" : 115,
      "context" : "Chemotherapy, which employs drug for specific inhibition of cancer cells, has been clinically accepted and widely used as one of the main approaches for cancer treatment all over the world.(117) However, it has been frequently observed that cancer cells show progressively",
      "startOffset" : 189,
      "endOffset" : 194
    }, {
      "referenceID" : 118,
      "context" : "insufficient water-solubility, instability, short circulation period, low selectivity, and nonspecific delivery, external stimulus-sensitive drug nanocarriers for cancer therapy has received tremendous attention.(120) The sensitivity of oxygen-enriched cells to chemotherapy are higher than hypoxic cells, while the sensitivity to PTT are reversed.",
      "startOffset" : 212,
      "endOffset" : 217
    }, {
      "referenceID" : 119,
      "context" : "The sensitivity of oxygen-enriched cells to chemotherapy are higher than hypoxic cells, while the sensitivity to PTT are reversed.(121) Hence, when combining PTT with chemotherapy, hyperthermia is capable of improving tumor sensitivity to anticancer drugs and the uptake rates of drugs, suppressing drug resistance, and increasing drug accumulation in tumor tissues, which are responsible for enhancing the therapeutic effect of chemotherapy.",
      "startOffset" : 130,
      "endOffset" : 135
    }, {
      "referenceID" : 120,
      "context" : "Hence, when combining PTT with chemotherapy, hyperthermia is capable of improving tumor sensitivity to anticancer drugs and the uptake rates of drugs, suppressing drug resistance, and increasing drug accumulation in tumor tissues, which are responsible for enhancing the therapeutic effect of chemotherapy.(122-124) Besides, these two therapies could function synergistically, giving higher therapeutic efficacy (Fig.",
      "startOffset" : 305,
      "endOffset" : 315
    }, {
      "referenceID" : 121,
      "context" : "Hence, when combining PTT with chemotherapy, hyperthermia is capable of improving tumor sensitivity to anticancer drugs and the uptake rates of drugs, suppressing drug resistance, and increasing drug accumulation in tumor tissues, which are responsible for enhancing the therapeutic effect of chemotherapy.(122-124) Besides, these two therapies could function synergistically, giving higher therapeutic efficacy (Fig.",
      "startOffset" : 305,
      "endOffset" : 315
    }, {
      "referenceID" : 122,
      "context" : "Hence, when combining PTT with chemotherapy, hyperthermia is capable of improving tumor sensitivity to anticancer drugs and the uptake rates of drugs, suppressing drug resistance, and increasing drug accumulation in tumor tissues, which are responsible for enhancing the therapeutic effect of chemotherapy.(122-124) Besides, these two therapies could function synergistically, giving higher therapeutic efficacy (Fig.",
      "startOffset" : 305,
      "endOffset" : 315
    }, {
      "referenceID" : 80,
      "context" : "93, 125, 126 Our results indicated that compared with conventional drug carriers, nanocarriers with good photothermal ability can not only remarkably increase the drug accumulation at targeted cancer cells/tissues, but also drastically decrease the systemic toxicity, and even potentially avoid under- or over-dosing.(82) Page 11 of 47 Journal of Materials Chemistry B",
      "startOffset" : 317,
      "endOffset" : 321
    }, {
      "referenceID" : 91,
      "context" : "Yin et al.(93) employed chitosan (CS) modified MoS2 nanosheets (MoS2-CS) as a chemotherapeutic drug nanocarrier to fabricate NIR-photothermal-triggered drug delivery carriers, facilitating the combination of chemotherapy and PTT into one system for cancer treatment (Fig.",
      "startOffset" : 10,
      "endOffset" : 14
    }, {
      "referenceID" : 107,
      "context" : "Similarly, Wang et al.(109) also reported that the PLGA-coated MoS2 could be used as a pH- and NIR-responsive nanocarrier to control the release of DOX.",
      "startOffset" : 22,
      "endOffset" : 27
    }, {
      "referenceID" : 109,
      "context" : "To further improve the drug release, Yang et al.(111) reported a coating of iron oxide pre-adsorbed WS2 with silica and PEG.",
      "startOffset" : 48,
      "endOffset" : 53
    }, {
      "referenceID" : 99,
      "context" : "To further enable nanocarrier with specific cancer cell targeting ability, Liu et al.(101) functionalized MoS2 nanosheets with FA-modified LA-PEG as a platform to load chemotherapy drugs, including DOX and 7-Ethyl-10-hydroxycamptothecin (SN38).",
      "startOffset" : 85,
      "endOffset" : 90
    }, {
      "referenceID" : 128,
      "context" : "The efficient generation of (1)O2 requires an optimum incorporation of three key components: photosensitizer, light, and oxygen.(130-133) However, tumor microenvironments are mostly hypoxic, which leads to low productivity of (1)O2 and hence limits therapeutic efficacy.",
      "startOffset" : 127,
      "endOffset" : 137
    }, {
      "referenceID" : 129,
      "context" : "The efficient generation of (1)O2 requires an optimum incorporation of three key components: photosensitizer, light, and oxygen.(130-133) However, tumor microenvironments are mostly hypoxic, which leads to low productivity of (1)O2 and hence limits therapeutic efficacy.",
      "startOffset" : 127,
      "endOffset" : 137
    }, {
      "referenceID" : 130,
      "context" : "The efficient generation of (1)O2 requires an optimum incorporation of three key components: photosensitizer, light, and oxygen.(130-133) However, tumor microenvironments are mostly hypoxic, which leads to low productivity of (1)O2 and hence limits therapeutic efficacy.",
      "startOffset" : 127,
      "endOffset" : 137
    }, {
      "referenceID" : 131,
      "context" : "The efficient generation of (1)O2 requires an optimum incorporation of three key components: photosensitizer, light, and oxygen.(130-133) However, tumor microenvironments are mostly hypoxic, which leads to low productivity of (1)O2 and hence limits therapeutic efficacy.",
      "startOffset" : 127,
      "endOffset" : 137
    }, {
      "referenceID" : 133,
      "context" : "134 To solve this problem, it is essential to combine PDT with PTT to develop a synergistic phototherapy, where PTT with hyperthermia may increase intratumoral blood flow which further transport more oxygen into cancer cells to improve PDT efficiency.(135) Recently, several studies have reported that 2D TMDCs possess great potential as a simple but powerful nanoplatform for combined PTT/PDT treatment of cancer.",
      "startOffset" : 251,
      "endOffset" : 256
    }, {
      "referenceID" : 73,
      "context" : "15 TMDCs are able to enhance PDT efficiency since hyperthermia increases cell membrane permeability and thus increase cellular uptake of PSs.(75) In this process, 2D TMDCs not only produce significance heat upon NIR light irradiation for PTT but also act as photosensitizer carriers for PDT.",
      "startOffset" : 141,
      "endOffset" : 145
    }, {
      "referenceID" : 135,
      "context" : "Moreover, it has been demonstrated that 2D TMDCs such as MoS2 own better (1)O2 production ability, 136 even than commercial photosensitizer protoporphyrin IX (PpIX).(137) Therefore, 2D TMDCs have a potential as the candidates for synergistic therapy of PDT and PTT in cancer treatment.",
      "startOffset" : 165,
      "endOffset" : 170
    }, {
      "referenceID" : 105,
      "context" : "Yong et al.(107) for the first time designed and fabricated bovine serum albumin (BSA)-coated WS2 nanosheets for in vitro PTT/PDT combined therapy of cancer.",
      "startOffset" : 11,
      "endOffset" : 16
    }, {
      "referenceID" : 104,
      "context" : "Furthermore, the first in vivo 2D TMDC-based PDT/PTT combined therapy in animal experiments was demonstrated by Liu et al.(106) They designed a chlorin e6 (Ce6)-loaded MoS2-PEG (MoS2-PEG/Ce6) nanosheets for combinatorial PDT/PTT of cancer therapy, as shown in Fig.",
      "startOffset" : 122,
      "endOffset" : 127
    }, {
      "referenceID" : 136,
      "context" : "MoS2 nanosheets exhibit a higher Ce6 loading ratio (weight ratio of Ce6 to MoS2) (~30%) than PEGylated graphene oxide (~15%).(138) The as-prepared MoS2-PEG/Ce6 could remarkably enhance intracellular delivery of Ce6 because mild hyperthermia is able to increase cell membrane permeability and significantly kill cancer cells when they are exposed to laser radiation with wavelengths at 808 nm (PTT effects) and 660 nm (PDT effects).",
      "startOffset" : 125,
      "endOffset" : 130
    }, {
      "referenceID" : 0,
      "context" : "However, there are also some limitations of RT: (1) requirement of elevated doses and injury to the nearby normal tissue; (2) developed resistance to the radiation; (3) low efficiency for hypoxic cancer cells.",
      "startOffset" : 48,
      "endOffset" : 51
    }, {
      "referenceID" : 1,
      "context" : "However, there are also some limitations of RT: (1) requirement of elevated doses and injury to the nearby normal tissue; (2) developed resistance to the radiation; (3) low efficiency for hypoxic cancer cells.",
      "startOffset" : 122,
      "endOffset" : 125
    }, {
      "referenceID" : 2,
      "context" : "However, there are also some limitations of RT: (1) requirement of elevated doses and injury to the nearby normal tissue; (2) developed resistance to the radiation; (3) low efficiency for hypoxic cancer cells.",
      "startOffset" : 165,
      "endOffset" : 168
    }, {
      "referenceID" : 143,
      "context" : "There are two general paths for the enhancement of nanomaterial-enabled radiosensitization.(145) The first is the improvement of the effectiveness of ionizing radiation,",
      "startOffset" : 91,
      "endOffset" : 96
    }, {
      "referenceID" : 119,
      "context" : "For example, hyperthermia can not only directly kill tumor cells but also act as a sensitizer in radiation treatment.(121) Heat can induce DNA double-strand breaks and cause protein aggregation to inhibit the repair of DNA damage especially in the case of ionizing radiation-induced DNA damage.",
      "startOffset" : 117,
      "endOffset" : 122
    }, {
      "referenceID" : 144,
      "context" : "Heat can induce DNA double-strand breaks and cause protein aggregation to inhibit the repair of DNA damage especially in the case of ionizing radiation-induced DNA damage.(146) So, 2D TMDCs (e.",
      "startOffset" : 171,
      "endOffset" : 176
    }, {
      "referenceID" : 92,
      "context" : "6).(94) The as-prepared WS2-PEG without any other component could produce significant heat upon 808 nm laser irradiation and simultaneously generate dose-enhancement effects of RT under",
      "startOffset" : 3,
      "endOffset" : 7
    }, {
      "referenceID" : 81,
      "context" : "Cheng et al.(83) also reported the use of PEG-modified Gd-doped WS2 as a multifunctional agent for photothermal combination cancer treatment (WS2:Gd-PEG).",
      "startOffset" : 12,
      "endOffset" : 16
    }, {
      "referenceID" : 82,
      "context" : "Later, Cheng et al.(84) continued to construct a novel multifunctional (64)Cu-labeled FeSe2/Bi2Se3-PEG nanostructure for multimodal image-guided photothermal-radiotherapy.",
      "startOffset" : 19,
      "endOffset" : 23
    }, {
      "referenceID" : 110,
      "context" : "In addition, Wang et al.(112) utilized MoS2 as photothermal agent and Bi2S3 as radiation dose-enhancing agent to obtain MoS2/Bi2S3-PEG nanocomposite (MBP) with a good biocompatibility.",
      "startOffset" : 24,
      "endOffset" : 29
    }, {
      "referenceID" : 112,
      "context" : "Chao et al.(114) labeled a widely used radioisotope (188)Re on PEGylated WS2 to construct a multifunctional nanotheranostics (188)Re-WS2-PEG (Fig.",
      "startOffset" : 11,
      "endOffset" : 16
    }, {
      "referenceID" : 145,
      "context" : "The aim of gene therapy (GT) is to introduce therapeutic genetic materials (such as DNA or small interfering RNA) into cells to compensate for abnormal genes or produce a beneficial protein, and ultimately kill cancer cells.(147) This process consists of three steps.",
      "startOffset" : 224,
      "endOffset" : 229
    }, {
      "referenceID" : 148,
      "context" : "To solve this problem, either viral nanovectors or non-viral nanocarriers have been employed to deliver DNA or siRNA into cells.(150) Unfortunately, the side-effects of viral",
      "startOffset" : 128,
      "endOffset" : 133
    }, {
      "referenceID" : 149,
      "context" : "150 Thus, non-viral gene delivery nanocarriers, such as polymer-, lipid-, and graphene-based systems, have been extensively explored over the past decades.(151)",
      "startOffset" : 155,
      "endOffset" : 160
    }, {
      "referenceID" : 148,
      "context" : "For example, Kou et al.(150) designed a promising gene delivery system, that is, positively charged MoS2-PEG-PEI (polyethylenimine), which could bind to the negatively charged small interfering RNA (siRNA) by electrostatic interaction.",
      "startOffset" : 23,
      "endOffset" : 28
    }, {
      "referenceID" : 114,
      "context" : "Ulteriorly, Zhang et al.(116) deeply explored the combination mechanism of PTT with GT (Fig.",
      "startOffset" : 24,
      "endOffset" : 29
    }, {
      "referenceID" : 92,
      "context" : "25 potential avenue to guide the therapeutic process, monitor the therapeutic response, avoid damage to surrounding healthy tissue, and finally eliminate the associated side effects.(94) Owing to their intrinsic physical especially optical properties, 2D TMDCs can be not only used as a photothermal agent as well as a platform for combination of PTT with other treatments, but also applied in biomedical imaging (Fig.",
      "startOffset" : 182,
      "endOffset" : 186
    }, {
      "referenceID" : 153,
      "context" : "absorbance of the 2D TMDCs makes them ideal for photoacoustic (PA) imaging, which has become a new technology with the advantage of cross-sectional “listening” of entire tumors at depths not available to microscopy and sensitivity not available to computed tomography (CT) imaging.(155-160) Liu et al.",
      "startOffset" : 280,
      "endOffset" : 290
    }, {
      "referenceID" : 154,
      "context" : "absorbance of the 2D TMDCs makes them ideal for photoacoustic (PA) imaging, which has become a new technology with the advantage of cross-sectional “listening” of entire tumors at depths not available to microscopy and sensitivity not available to computed tomography (CT) imaging.(155-160) Liu et al.",
      "startOffset" : 280,
      "endOffset" : 290
    }, {
      "referenceID" : 155,
      "context" : "absorbance of the 2D TMDCs makes them ideal for photoacoustic (PA) imaging, which has become a new technology with the advantage of cross-sectional “listening” of entire tumors at depths not available to microscopy and sensitivity not available to computed tomography (CT) imaging.(155-160) Liu et al.",
      "startOffset" : 280,
      "endOffset" : 290
    }, {
      "referenceID" : 156,
      "context" : "absorbance of the 2D TMDCs makes them ideal for photoacoustic (PA) imaging, which has become a new technology with the advantage of cross-sectional “listening” of entire tumors at depths not available to microscopy and sensitivity not available to computed tomography (CT) imaging.(155-160) Liu et al.",
      "startOffset" : 280,
      "endOffset" : 290
    }, {
      "referenceID" : 157,
      "context" : "absorbance of the 2D TMDCs makes them ideal for photoacoustic (PA) imaging, which has become a new technology with the advantage of cross-sectional “listening” of entire tumors at depths not available to microscopy and sensitivity not available to computed tomography (CT) imaging.(155-160) Liu et al.",
      "startOffset" : 280,
      "endOffset" : 290
    }, {
      "referenceID" : 158,
      "context" : "absorbance of the 2D TMDCs makes them ideal for photoacoustic (PA) imaging, which has become a new technology with the advantage of cross-sectional “listening” of entire tumors at depths not available to microscopy and sensitivity not available to computed tomography (CT) imaging.(155-160) Liu et al.",
      "startOffset" : 280,
      "endOffset" : 290
    }, {
      "referenceID" : 104,
      "context" : "Liu et al.(106) reported that prominent PA signals were seen in the tumor 24 h after i.",
      "startOffset" : 10,
      "endOffset" : 15
    }, {
      "referenceID" : 159,
      "context" : "Chen et al.(161) found that the photoacoustic effect of the MoS2 nanosheets is highly dependent on the number of layers.",
      "startOffset" : 11,
      "endOffset" : 16
    }, {
      "referenceID" : 92,
      "context" : "In addition, since 2D TMDCs containing high Z number atom such as W and Bi have high X-ray absorption coefficient, they are reported to be suitable candidates for CT imaging contrast agents to afford high-resolution 3D structural details of the whole body.(94) For example, RABIN et al.",
      "startOffset" : 256,
      "endOffset" : 260
    }, {
      "referenceID" : 164,
      "context" : "For example, RABIN et al.(166) and Li et al.",
      "startOffset" : 25,
      "endOffset" : 30
    }, {
      "referenceID" : 165,
      "context" : "and Li et al.(167) reported that Bi2Se3 nanosheets showed excellent X-ray attenuation and could be utilized for enhanced X-ray CT imaging of tumor tissue in vivo.",
      "startOffset" : 13,
      "endOffset" : 18
    }, {
      "referenceID" : 167,
      "context" : "Besides, one of the great disadvantages exist in optical imaging is the weak tissue penetration.(169) Accordingly, multi-modal bio-imaging have become a blooming trend in the development of molecular imaging (Table 2).",
      "startOffset" : 96,
      "endOffset" : 101
    }, {
      "referenceID" : 169,
      "context" : "170 Cheng et al.(171) also explored PA and CT imaging behaviour of WS2-PEG nanosheets.",
      "startOffset" : 16,
      "endOffset" : 21
    }, {
      "referenceID" : 168,
      "context" : "29 functionalized with PEG and then employed it as photothermal as well as contrast agent in dual-modal PA and MR imaging.(170) Yang et al.",
      "startOffset" : 122,
      "endOffset" : 127
    }, {
      "referenceID" : 109,
      "context" : "also reported that Fe3O4 nanoparticles could be non-covalently attached to the surface of WS2 to form WS2/Fe3O4 suspensions for multimodal PA and MR imaging of tumor tissues.(111) Those two efforts demonstrated that Fe3O4 decorated MoS2 and WS2 could magnetically target to photothermal ablation of cancer indicated by PA and MR imaging.",
      "startOffset" : 174,
      "endOffset" : 179
    }, {
      "referenceID" : 81,
      "context" : "In addition, Cheng et al.(83) prepared Gd doped-WS2 nanosheets that could be utilized for a combined PTT and RT of cancer under tri-modal (CT, PA and MRI) image guidance.",
      "startOffset" : 25,
      "endOffset" : 29
    }, {
      "referenceID" : 82,
      "context" : "Cheng and co-workers further designed a novel multifunctional nano-probe based on a FeSe2/Bi2Se3 nanocomposite which was modified by PEG via hydrophobic interactions.(84) Using its high NIR and X-ray absorbance, strong magnetic property as well as radioisotope labeling, multi-modal in vivo tumor imaging with (64)Cu-FeSe2/Bi2Se3 was realized, including PA, CT, MR, and PET imaging.",
      "startOffset" : 166,
      "endOffset" : 170
    }, {
      "referenceID" : 97,
      "context" : "The safety of nanomaterials is of great importance for their applications in the field of nanomedicine.(99) 2D TMDCs, similar to graphene nanosheets, possess layered structures and may not be easily bio-degraded in the living system.",
      "startOffset" : 103,
      "endOffset" : 107
    }, {
      "referenceID" : 171,
      "context" : "On one hand, the cytotoxicity may vary with the different synthesis methods and situations.(173) For example, Appel et al.",
      "startOffset" : 91,
      "endOffset" : 96
    }, {
      "referenceID" : 45,
      "context" : "For example, Appel et al.(46) demonstrated that, through a series of biocompatibility tests, pristine 2D TMDCs (ME-WS2, ME-MoS2 and CVD MoS2) did not induce the decrease of cellular viability or genetic defects, which paved a way for the use of 2D ME-WS2, Page 29 of 47 Journal of Materials Chemistry B",
      "startOffset" : 25,
      "endOffset" : 29
    }, {
      "referenceID" : 173,
      "context" : "Moreover, the research of Shi group demonstrated that PEGylated MoS2 nanosheets showed no significant cytotoxicity at a series of concentrations, even up to 500 μg mL.(175) On the other hand, the cytotoxicity may vary with different compounds.",
      "startOffset" : 167,
      "endOffset" : 172
    }, {
      "referenceID" : 175,
      "context" : "materials associated with different transition metal element (Vanadium) as well as the chalcogen type.(177) As shown in Fig.",
      "startOffset" : 102,
      "endOffset" : 107
    }, {
      "referenceID" : 160,
      "context" : "For example, Qian et al.(162) showed that after i.",
      "startOffset" : 24,
      "endOffset" : 29
    }, {
      "referenceID" : 85,
      "context" : "injection.(87) Notably, the PEGylated 2D TMDCs mainly",
      "startOffset" : 10,
      "endOffset" : 14
    }, {
      "referenceID" : 176,
      "context" : "It is well known that the challenges and obstacles still exist in the road of the translation of nanotheranostics into medicine.(178-183) Therefore, in the near further, there will be a large number of research areas that are particularly promising.",
      "startOffset" : 127,
      "endOffset" : 137
    }, {
      "referenceID" : 177,
      "context" : "It is well known that the challenges and obstacles still exist in the road of the translation of nanotheranostics into medicine.(178-183) Therefore, in the near further, there will be a large number of research areas that are particularly promising.",
      "startOffset" : 127,
      "endOffset" : 137
    }, {
      "referenceID" : 178,
      "context" : "It is well known that the challenges and obstacles still exist in the road of the translation of nanotheranostics into medicine.(178-183) Therefore, in the near further, there will be a large number of research areas that are particularly promising.",
      "startOffset" : 127,
      "endOffset" : 137
    }, {
      "referenceID" : 179,
      "context" : "It is well known that the challenges and obstacles still exist in the road of the translation of nanotheranostics into medicine.(178-183) Therefore, in the near further, there will be a large number of research areas that are particularly promising.",
      "startOffset" : 127,
      "endOffset" : 137
    }, {
      "referenceID" : 180,
      "context" : "It is well known that the challenges and obstacles still exist in the road of the translation of nanotheranostics into medicine.(178-183) Therefore, in the near further, there will be a large number of research areas that are particularly promising.",
      "startOffset" : 127,
      "endOffset" : 137
    }, {
      "referenceID" : 172,
      "context" : "For example, as mentioned before, MoS2 exhibits stronger toxicity with increased exfoliation.(174) Thus, it is necessary to establish a standardization for the preparation",
      "startOffset" : 93,
      "endOffset" : 98
    }, {
      "referenceID" : 181,
      "context" : "Sharifi et al.(184) discussed that toxicity of nanomaterials is closely connected with physicochemical properties, such as size, surface chemistry, shape, protein absorption gradient and surface smoothness or roughness.",
      "startOffset" : 14,
      "endOffset" : 19
    }, {
      "referenceID" : 182,
      "context" : "Fischer et al.(185) emphasized the need for in vivo studies to accurately assess nanotoxicity since most reported nanotoxicity studies in vitro cell culture are not correspondent to in vivo results.",
      "startOffset" : 14,
      "endOffset" : 19
    } ],
    "year" : 2017,
    "abstractText" : "Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the ethical guidelines, outlined in our author and reviewer resource centre, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. Accepted Manuscript",
    "creator" : "Aspose Ltd."
  }
}